Podcasts about i ii

El Dr. Efreén Horacio Montaño Figueroa, hematólogo adscrito al Hospital General de México “Dr. Eduardo Liceaga” en la Ciudad de México, México, junto con la Dra. Anna María Sureda Balari, hematólogo y jefa de Servicio de Hematología Clínica en el Institut Català d'Oncologia en Barcelona, España, nos comentan sobre lo más destacado en hematología presentado en ASCO 2021, resaltando los siguientes estudios: Linfoma de células del manto: Abstract 7505: Estudio fase I, multicéntrico, de etiqueta abierta, que evalúa la seguridad y eficacia de la combinación de venetoclax + lenalidomida + rituximab en 28 pacientes con linfoma de células del manto no tratado previamente. Linfoma no Hodgkin: Abstract 7519: Estudio fase I, multicéntrico, que evaluó la dosis de glofitamab administrado después de un pretratamiento de dosis fija única de obinutuzumab en pacientes con linfoma no Hodgkin de células B en recaída / refractario. ZUMA-5: Estudio fase II, multicéntrico, que evaluó la tasa de respuesta objetiva de leucocitaféresis + quimioterapia de acondicionamiento seguida de una infusión de axicabtagene ciloleucel como tratamiento para 94 pacientes con linfoma no Hodgkin indolente en recaída / refractario. Abstract 7518: Estudio fase I/II, de etiqueta abierta, que evaluó la seguridad de epcoritamab subcutáneo en 68 pacientes con linfoma no Hodgkin de células B en recaída / refractario. Linfoma de Hodgkin: Alliance: Estudio que evaluó la terapia adaptada a la respuesta basada en la tomografía por emisión de positrones (PET, por sus siglas en inglés) para 101 pacientes con linfoma de Hodgkin voluminoso en estadio I y II. Leucemia mieloide aguda: Abstract 7018: Subanálisis del estudio fase III, aleatorizado, doble ciego, VIALE-A, que evaluó venetoclax + azacitidina vs. azacitidina sola en 286 pacientes con leucemia mieloide aguda. Leucemia linfoblástica aguda: Zuma-3: Estudio fase I/II, multicéntrico, de etiqueta abierta, que evalúa la remisión completa y eficacia de brexucabtagene autoleucel (KTE-X19) en 71 pacientes con leucemia linfoblástica aguda de células B en recaída / refractario. Mieloma múltiple: Abstract 8017: Actualización del estudio fase III, multicéntrico, aleatorizado, de etiqueta abierta ICARIA-MM, que compara isatuximab + pomalidomida + dexametasona vs. pomalidomida + dexametasona en 307 pacientes con mieloma múltiple en recaída/refractario. KarMMa: Estudio fase II, multicéntrico, de etiqueta abierta, de un solo brazo, que evaluó la eficacia y seguridad de idecabtagene vicleucel en 140 pacientes con mieloma múltiple en recaída / refractario.

Dr. Mitul Gandhi, medical oncologist-hematologist at Virginia Cancer Specialists of the US Oncology Network, highlights therapeutic advances in multiple myeloma featured at the 2021 ASCO Annual Meeting.   Transcript:  ASCO Daily News: Welcome to the ASCO Daily News Podcast. I'm Geraldine Carroll, a reporter for the ASCO Daily News. My guest today is Dr. Mitul Gandhi, a medical oncologist specializing in hematologic malignancies at Virginia Cancer Specialists, which is part of the US Oncology Network. Dr. Gandhi will discuss therapeutic advances in multiple myeloma featured at the 2021 ASCO Annual Meeting. He reports no conflicts of interest relating to our discussion today, and full disclosures relating to all episodes of the podcast are available on our transcripts at asco.org/podcasts. Dr. Gandhi, welcome to the ASCO Daily News podcast. Dr. Mitul Gandhi: Thank you for having me. ASCO Daily News: Let's first look at the OPTIMUM MUKnine trial. It's Abstract 8001. And it reported high overall response rates in patients with ultra high-risk multiple myeloma with Dara-CVRd induction therapy. What are your takeaways from this study, Dr. Gandhi? Dr. Mitul Gandhi: Sure. So, the OPTIMUM study was conducted by the UK group, and it's noteworthy for several reasons. The way they had constructed the trial, they designed and developed a platform primarily to enrich for a predefined subset of very high-risk individuals, whether it was through a set of genetic assessment or with central gene expression profiling. And the way the trial was conducted, while patients were waiting to ascertain the results of the gene expression profiling (GEP) they could receive two cycles of bridging therapy. Once those results were furnished or they met the cytogenetic risk criteria, patients who subsequently consented to the intervention protocol which was a dose intensified regimen, five drug regimen, incorporating daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone. So, patients would receive induction for up to six cycles, and that would include the two cycles of potential bridging therapy as GEP was being evaluated on an every 21 day basis. And then this was followed by a modified conditioning regimen consisting of high-dose melphalan at 200 milligrams per meter squared along with weekly bortezomib which was continued even following autologous stem cell rescue, really until count recovery. Subsequently, patients received an additional six cycles of daratumumab, bortezomib, revlimid, or lenalidomide followed by 12 cycles of daratumumab and rituximab until progression. This was a complex study design with an intensified induction consolidation and maintenance phase, but it did yield a impressively high OR rate, or overall response rate, at 94% with very good partial response or greater seen in 77% after assessment following autologous transplantation, including 46% complete response (CR). And of those with CR, they had identified 63% achieving MRD negativity as well. And I think the authors should be commended for one, enriching a high-risk subset of patients both on conventional cytogenetics and/or GDP, and then two, utilizing the most active agents that we currently have to elicit high responses and then to consolidate on those following transplant. I think some of the take homes from the study are the ability to demonstrate feasibility of central genomic risk stratification related to more precisely identify and select high-risk patients as this is kind of an area of unmet need of where to augment therapy appropriately. I think it's still a question whether or not this is the exact dose intensified regimen that's going to elicit the best long-term outcomes in these highest risk patients and whether or not the conventional surrogates for a long-term progression-free survival (PFS) benefits such as MRD really apply to this as there is some controversy regarding that. Nonetheless, I think this offers a kind of a reproducible platform that can be emulated to identify the highest risk patients. You can do that prospectively, and then to selectively incorporate the most active agents and potentially the next generation of novel agents, including immunomodulators, cellular therapy, bi-specific antibodies earlier in the treatment course, and really try to elicit the deepest initial response and hopefully see that translate into longer term durable control. So, this was a complex study design that was impressively executed, and again with an ability to enrich for the highest risk subsets. ASCO Daily News: Excellent. Thanks for sharing your takeaways from the OPTIMUM trial. Well let's focus on the phase II CARTITUDE-2 study. That's Abstract 8013. This study reported that deep and early responses were yielded with a single infusion of cilta-cel in patients who had received one to three prior lines of therapy for multiple myeloma. What are your thoughts on this trial? Dr. Mitul Gandhi: So, Dr. Usmani presented the CARTITUDE-2 update on behalf of his co-collaborators. And the listeners probably are aware of some of the preliminary data that was presented at ASH as well in 2020, but this is a phase I/II protocol. Currently the phase II data are being presented with a proprietary CAR T platform which has two BCMA single domain antibodies on the CAR T construct along with a co-stimulator domain. And as kind of summarized in the title, the single dose was infused. So, amongst 113 patients who were initially recruited, 97 ultimately were treated with some fallout attributed to progressive disease. Like many of the other CAR T studies, this was a uniformly high-risk and heavily pretreated population. Median age was 61. High-risk cytogenetics were in 23% of patients. And there was about 20% of patients who had harbored plasma cytomas as well. Response rates were impressively high at almost 98%, and 67% obtaining a stringent complete response (CR). Much like the other CAR T experience, response continued to deepen over time. And encouragingly, duration of response was actually not reached time of presentation. Kind of amplifying the depth of response, of the patients assessable for MRD, 93% had achieved an MRD negative state at a sensitivity of 10 to the minus fifth cells, leading to a 12-month PFS of 77% and an OS of 89%. So, these are all welcome numbers and response data, again, in a heavily pretreated population who have been exposed to what we believe all the more active agents in the disease. In parallel with kind of response, with particularly with CAR T is the toxicity data. And encouragingly, while CRS, or cytokine release syndrome, which is typified in CAR T therapy was seen in about 95% of patients, only 4% had grade 3 to 4 CRS. So, on the whole, quite manageable. Median time to onset was 7 days with duration of 4 days and resolved with appropriate medical therapy, including tocilizumab. They did report one patient who had grade 5 CRS with hemophagocytic lymphohistiocytosis (HLH) with the remainder, I was summarizing kind of the low level of grade 3, 4 experience. There was additionally neurotoxicity and 21%, with 10% having grade 3 or higher. Again, resolved with supportive care measures. So, in totality this builds on the CAR T experience with high response rates, deep response, rates including achievement of stringent CR and high rates of MRD negativity with only a single dose of CAR T cells infused, again amplifying the efficacy of this platform on a heavily pretreated population and potentially allowing for extended treatment-free intervals as well or options for retreating in people who don't achieve MRD with a manageable toxicity profile at experienced centers. Certainly there's still work that's going to be done to better delineate the extent of CRS and how to appropriately treat that along with the neurotoxicity, but along with several other abstracts presented at this meeting and meetings prior, builds on the CAR T experience, knowledge rapidly coming to the forefront in myeloma therapy. ASCO Daily News: Great. So, some good developments for previously treated patients. Well, now I'd like to focus on newly diagnosed multiple myeloma. Let's look at the CARDAMON trial, Abstract 8000, and the FORTE trial, Abstract 8002. These studies explored novel therapies that are emerging for newly diagnosed multiple myeloma. So in their presentations, these trial investigators seem to question the value of standard of care autologous stem cell transplant (ASCT). So do you think these new data call into question the advantages of the up front ASCT approach in newly diagnosed multiple myeloma? Dr. Mitul Gandhi: That's a great question. And as providers in the myeloma community know, there's still an ongoing debate whether or not to ubiquitously apply a high dose melphalan conditioning and stem cell rescue across the spectrum of all patients with myeloma who are transplant eligible or reserving it for certain patients or not. Some of this is borne out of saving unnecessarily aggressive therapy, who would otherwise achieve an excellent response of induction. Along with some concern for secondary genotoxic effects imparted by the melphalan itself and perhaps propagating more biologically aggressive subclones. And to that end, these two abstracts explored whether or not transplant-free approaches would be feasible. So, the CARDAMON study enrolled 281 patients where all patients received kyprolis, cyclophosphamide, and dexamethasone for four cycles, and of those patients achieving at least a partial response (PR), they were subsequently randomly assigned to continuous KCd or autologous stem cell transplant. And what the authors concluded, KCd induction followed by KCd maintenance was not inferior to autologous stem cell transplant with PFS at 2 years measured at 70% versus 76%, and that difference meeting the criteria that was prespecified in terms of their confidence interval for noninferiority. So, on the surface you could argue based on the results that were presented that there was equivalence. But a few caveats that are important to bring up, the first was that follow-up was short. It was only two years, and so it's very plausible that with longer follow up, the noninferiority that was seen may not be borne out with extended follow up. The other point the author's note was that MRD negativity was higher in the autologous stem cell group at 53% compared to 35.8% of the non-transplant group. And various studies have reported this to be a reasonable surrogate for long-term PFS, not always. And so again highlights the fact that with longer follow up, we may see a separation of the curves. Their subset analyses did not demonstrate any obvious areas, rather a subset of patients that would have derived preferential benefit, although the numbers were quite small. So, while an initial conclusion may be that there was a relative equivalence for a transplant-free approach, I'd argue that it's probably still a bit premature to make that conclusion and noninferiority may not be identical with longer follow up. And additionally, this probably is an induction regimen that is not as commonly employed in the U.S. But it does again help to the body of literature regarding this question of transplant for all versus not, although there may be hopefully more discriminatory power to see where it would be beneficial. The FORTE study presented by Dr. Gay and her colleagues was a bit larger at 464 patients and slightly different. Patients were randomly assigned to one of three arms, carfilzomib plus cyclophosphamide plus dexamethasone for four cycles induction followed by autologous stem cell rescue, carfilzomib, lenalidomide, dexamethasone induction for four cell cycles followed by autologous stem cell rescue, or carfilzomib, lenalidomide, dexamethasone without autologous stem cell for 12 cycles. So, those were the three arms, and then there was a second randomization to lenalidomide versus lenalidomide plus carfilzomib maintenance. Patients were prespecified in terms of their cohorts of high-risk, standard risk, or the so-called double hit which was people, patients rather, harboring two high-risk cytogenetic features. And so what the authors concluded that across the board, the arm containing carfilzomib, lenalidomide, dexamethasone with autologous stem cell rescue demonstrated superior PFS compared to all of the other, rather, the other two arms. And similarly intensification of maintenance incorporating kyprolis plus revlimid resulted in superior 3 year PFS compared to revlimid alone in 90% versus 73%. So what do we take away from this? Well, it's not a conventional induction approach in the U.S., with RVd still predominantly being used, particularly after the endurance data was presented at last year's ASCO showing equivalence of a bortezomib induction strategy versus carfilzomib strategy. It does support and lend credence to the use of high dose melphalan autologous stem cell rescue as patients who are in this arm seem to enjoy a more longer and durable progression-free survival across all subsets, including standard risk, high-risk, and the double hit strategy. So there wasn't any particular subset that could be identified that would have performed equally well with KRd alone without autologous stem cell rescue. Putting these two abstracts together, I would still argue that there remains a very important role for our high dose melphalan and autologous stem cell rescue currently an induction, rather following induction, in appropriately selected patients. And while we may not have identified patients on preselected criteria based on their cytogenetic risk, it's conceivable that we might identify response based criteria, whether it's MRD or otherwise, to perhaps see who may be able to abstain from transplantation. And there are several protocols that are actively accruing, some that have been preliminarily presented, and some that will be presented in subsequent meetings that might lend evidence to this. But for now based on the data sets that were presented at this year's meeting at ASCO, there still seems to be support for use of high dose melphalan and autologous stem cell rescue. ASCO Daily News: Right. Well staying with the issue of transplantation, for over a decade investigators have been exploring the curative ability of alloHCT in select patients with high-risk multiple myeloma. Fast forward to 2021 and the phase II double blind, placebo controlled, blood and marrow transplant clinical trials network 1302 trial. That's Abstract 7003. This study found that when performed with a reduced intensity conditioning regimen of bortezomib, fludarabine, and melphalan, alloHCT was safe in patients with high-risk multiple myeloma. What are your thoughts on this, and do you anticipate further research on the role of alloHCT in patients with multiple myeloma and high-risk features? Dr. Mitul Gandhi: So, this is an interesting abstract presented by Dr. Nishihori and her colleagues specifically looking at the role of ixazomib maintenance following a reduced intensity conditioning regimen of fludarabine, melphalan, and bortezomib in patients with high-risk myeloma. So this study was a phase II study enrolling patients under the age of 70 with high-risk myeloma defined by cytogenetics, or presence of plasma cell leukemia, or relapse within 24 months of an autologous stem cell transplant, which has been identified as a prognostic factor independent of baseline risk of poor outcomes, with the goal of administering the reduced intensity conditioning followed by HLA matched donor unmanipulated graft with methotrexate and tacrolimus GVHD prophylaxis, and starting at day 60, randomization ixazomib versus placebo maintenance. It should be noted that the goal initially was to enroll 110 patients, but ultimately only 57 patients were accrued over the course of 4 years from 2015 to 2018, 52 ultimately receiving an allogeneic HCT and 43 proceeding to maintenance. And so this in and of itself highlights the challenges of running an alginate transplant trial in myeloma mainly because sick patients may be by the point where allogeneic transplant is being entertained or inability to achieve sufficient disease control in order to pursue the transplant. But with respect to the study itself, they reported a PFS and overall survival (OS) outcome at 24 months, of 52% and 85% respectively, with transplant-related mortality at a respectable 11%. So in context of the small studies that had previously been reported in this space of allo SCT and myeloma, this was improved treatment-related mortality related to the procedure itself. With respect to the question at hand regarding the role of ixazomib maintenance, interestingly they showed no difference in PFS, with ixazomib versus placebo at 55% and 59% and OS at 95% and 87%. In terms of the toxicity, it was not trivial. Grade 3 to 4 acute GVHD at day 100 was 9.5% in the ixazomib arm, 0% in the placebo arm. And chronic GVHD was 69% versus 64%. So, where do we take all of this data in context? I think there is a signal of lower transplant-related mortality compared to historical controls, and so it probably speaks to the improved ability to identify patients and also get them through transplant with this modified conditioning. The follow up, however, was abbreviated, and so there may be increased relapse over time as well. In terms of where does this fit in the armamentarium of therapy with refractory myeloma, I think that's still to be determined. And perhaps it's going to be occupying more of a niche role given the blossoming repertoire of highly efficacious immune-based agents, whether it's modified cellular therapy with CAR T a upcoming NK cell products that are being explored, and of course by specifically antibodies that have been robustly presented at this meeting demonstrating impressive responses. So, it's very conceivable that patients who were previously would be entertained for allogeneic SCT will now be in are treated with this kind of repertoire of novel immune agents. And so it may become a more of a niche role in patients who have exhausted all conventional or investigational approaches, but it does suggest that with this modified reduced intensity conditioning, treatment-related mortality can be lowered. With respect to the question at hand, it does not appear as though maintenance ixazomib helps these patients. And so observation alone following transplant versus an alternative maintenance strategy would be indicated. ASCO Daily News: OK. Well I'd like to ask you about the Apollo trial. That's Abstract 8046. This study looked at health-related quality of life of previously treated patients with multiple myeloma on a regimen of pomalidomide and dexamethasone plus subcutaneous daratumumab. Any surprises here, Dr. Gandhi? Dr. Mitul Gandhi: So, the Apollo study is a phase III trial primarily evaluating the efficacy of pomalidomide plus dexamethasone versus pomalidomide dexamethasone plus the incorporation of subcutaneous daratumumab in patients with myeloma who had received one prior line of therapy. And primary outcomes data had already been presented with improved rates of disease control with incorporation of daratumumab. With respect to this abstract, Dr. Terpos presented quality of life and patient-reported outcomes that was collected in parallel with the intervention arm of this study, and so they utilized the EORTC 30 item questionnaire to assess quality of life and subjective data from patients. And what they found was in the patients who had been on the DPD arm, or the daratumumab arm, there was a greater reduction in pain and no real augmentation or introduction of increased adverse events related to the additional agent. Moreover, there was no decline in physical or emotional functioning with DPD, but there was worsening decline in those elements compared to baseline for patients receiving pomalidomide and dexamethasone alone. There were higher rates of improvement with respect to control of disease symptoms, physical functioning, emotional functioning on the DPD arm. So, what does this tell us? Well in general, I think we've seen a plethora of agents that have improved outcomes with our patients with myeloma who are now living for years on therapy, increasingly and often even into a second decade. And so gaging the impact of therapy on quality of life, subjective sense of well-being is critical as these patients are going to be on therapy for quite a while. And so independent of serologic and laboratory response, we certainly want the interventions to improve functional capacity. And this data would suggest that you can achieve that in parallel with achieving better and deeper responses, which intuitively makes some sense, and they are often congruous. Involving the incorporation of an additional agent didn't worsen the sense of adverse events, but in fact improved the general sense of well-being. So this adds to the body of work of daratumumab on a MM dexamethasone backbone parting benefit without toxicity and also lending credence to the notion that by improving myeloma parameters, we're going to be in parallel improving quality of life. And so with the advent of all the other agents and novel compounds that are being developed after the acute toxicity period, we'd also expect to see improvement in quality of life as well. And so I think this was an important contributor to telling us this. ASCO Daily News: Excellent. Well thank you so much, Dr. Gandhi. I really appreciate your time today. Before we wrap up, any final thoughts from you on advances in multiple myeloma? There's certainly some really impactful work being done in the field. Dr. Mitul Gandhi: Yeah. I think I would encourage all the listeners to review the abstracts presented, particularly the oral abstracts as they get into some of the granularity on detail regarding the individual CAR T and bispecific antibody products, and very nicely demonstrate the durable responses that are being achieved in heavily pre-treated patients. Obviously kind of the next sort of hurdle in the field is to democratize these agents and make sure they're readily available for all patients. And there's a lot of work being done to ensure that management of the acute toxicity can be managed more broadly. So I think I'd pay particular attention to the oral abstract sessions which really demonstrate the novel agents that are being investigated. ASCO Daily News: Dr. Gandhi, thanks again for being on the podcast today to highlight some great new therapies in multiple myeloma. Dr. Mitul Gandhi: Thank you for having me. ASCO Daily News: And thank you to our listeners for your time today. If you enjoyed this episode, please take a moment to rate and review us wherever you get your podcasts.   Disclosures: Dr. Mitul Gandhi: None disclosed.  Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Dr. Stephen Liu, associate professor of medicine and director of Thoracic Oncology and Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, highlights key abstracts in lung cancer featured at the 2021 ASCO Annual Meeting.   Transcript:  ASCO Daily News: Welcome to the ASCO Daily News Podcast. I'm Geraldine Carroll, a reporter for the ASCO Daily News. My guest today is Dr. Stephen Liu. He is an associate professor of medicine and the director of thoracic oncology and developmental therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. Dr. Liu joins me to highlight advances in lung cancer featured at the 2021 ASCO Annual Meeting. Dr. Liu has served in a consulting or advisory role for Genentech, Pfizer, and AstraZeneca, among other organizations. His full disclosures and those relating to all episodes of the podcast are available on our transcripts at ASCO.org/podcasts. Dr. Liu, it's great to have you on the podcast today. Dr. Stephen Liu: Thanks for having me. ASCO Daily News: Dr. Liu, a lot of people were talking about the IMpower010 study during the annual meeting. That's abstract 8500, an interim analysis that showed really promising results for patients with resected non-small cell lung cancer. Can you tell us about this practice-changing study? Dr. Stephen Liu: Well, IMpower010 was a global randomized phase III trial, and I think this really was one of the highlights of the ASCO Annual Meeting from a lung cancer standpoint. As a reminder, our current standard of care is cisplatin-based chemotherapy for patients with resected stage II to III non-small cell lung cancer and for select patients with stage IB. We know from decades of experienced multiple phase III trials, large meta-analyses, that the risk of recurrence is quite high for resected stage II/III lung cancer. And the use of up to four cycles of cisplatin-based chemotherapy does lead to an improvement in survival, and that's our standard of care. That survival improvement, however, is modest, with an absolute improvement and 5-year survival of about 5%. And so we've been trying to improve outcomes in this setting for quite some time. We know from last year's ASCO that the subset of patients whose tumor harbors an EGFR mutation received some benefit from disease-free survival with the use of adjuvant osimertinib. IMpower010 presented at this year's ASCO by Dr. Heather Wakelee looks at the use of immunotherapy as a complementary adjuvant therapy. And we knew from press release that this study had met its primary endpoint. This was our first chance to look at the data first-hand and really see how it would impact practice. And I think the data were quite impressive. It's a fairly simple design. This study included patients with completely resected stage IB to IIIA non-small cell lung cancer, either histology. Note that this used AJCC version 7, and so the stage IB that were included had a size of at least four centimeters, and that's the subset that seems to derive the most benefit from chemotherapy. Now patients received cisplatin-based chemotherapy one to four cycles first. And those who received at least one cycle of chemotherapy were then randomly assigned 1 to 1 to receive 1 year of atezolizumab, PD-L1 inhibitor, or best supportive care. This was a large study, over 1,000 patients randomly assigned. It began enrollment in 2014. So it did include some EGFR and some ALK when maybe we didn't know quite as much about including those patients in these studies, but the EGFR was about 12%, the ALK was 3%. Some were unknown EGFR and ALK status, but these were likely the squamous histology, as those numbers line up. The PD-L1 testing, importantly, was done by the VENTANA SP263 assay, looking at tumor cell expression only, which is a fairly straightforward assay. And what we saw after a median follow up of almost 3 years was that in the primary high-risk population stage II to IIIA resected non-small cell lung cancer with the PD-L1 expression of at least 1%, the use of adjuvant atezolizumab significantly improved disease-free survival. And the hazard ratio there was 0.66. If we look at the 2-year disease-free survival (DFS) rate, it improved from 61% with best supportive care to 75%, and at 3-year DFS from 48% to 60%. So an improvement in the 3-year DFS rate and a hazard ratio of 0.66. The fourth plot showed that signal was greater in node-positive. As expected, no signal in that ALK subset, though it was small. But this is a pretty substantial improvement in disease-free survival. When we look at these Kaplan-Meier curves, they split immediately, really right at the first scan. And when we look at a study like this, this phase III trial, it reminds us how poor our current standard is; how many patients do suffer relapse and recurrence and death from this potentially curable cancer. Atezolizumab clearly improving outcomes in this subset. We then saw analyses of the resected stage II to III across PD-L1 strata, so positive and negative. And there the hazard ratio, as expected, less impressive, 0.79. If we look at the forest plot there, the hazard ratio for PD-L1 high, using that 50% cutoff we're used to, was substantial at 0.43. So overall, the DFS and PD-L1 positive 0.66 and the PD-L1 high 0.43. So no report on the PD-L1 low, which is what we're waiting for, that one at 49%, presumably not as impressive as 0.66. And we'll wait for those data to come out. But PD-L1 positive, a clear benefit. PD-L1 high, a substantial benefit. That's really where the formal analyses stopped. The stage IB to IIIA overall population was too immature for analysis, and overall survival was not yet formally tested. This will take a few years to breathe out. They did provide an early look at overall survival. And in that stage II to IIIA PD-L1 positive, there was the right trend, with a hazard ratio of 0.77, though not statistically significant. We did see these curves start to come apart at about 12 to 18 months, which is what you would expect if this study ultimately would lead out to be positive. We do want to wait for OS results. But one has to wonder, is a DFS benefit this substantial enough to change practice? And atezolizumab not yet approved in this setting, but the trial did meet its primary endpoint. And to me, for PD-L1 positive, and certainly for PD-L1 high, I do think these data aren't practice- changing. ASCO Daily News: Absolutely. Well, another trial that attracted a lot of attention was the CheckMate-816 trial. That's Abstract 8503. What can you tell us about the surgical outcome data reported in CheckMate-816? Dr. Stephen Liu: So CheckMate- 816 was a randomized phase III trial that looked at neoadjuvant therapy. So this also focused on resectable lung cancer. This is an area where we hope for cure, but for some of the more advanced stages, we don't necessarily expect it. Much room for improvement. We saw the IMpower010 data showing adjuvant immunotherapy improved DFS. Here we're looking at the neoadjuvant space. And at AACR in 2021, Dr. Patrick Forde presented some of the early PCR results. And that showed the pathologic complete response rates with neoadjuvant nivolumab plus chemotherapy for three cycles was superior to chemotherapy alone for three cycles. So the addition of nivolumab to chemotherapy improved the pathological CR rate from 2% to 24%. Really astounding. What Dr. Jonathan Spicer presented at ASCO 2021 were the surgical outcomes from that study. And we see that adding immunotherapy to chemotherapy significantly improves the pathologic CR rate. Does it come at a cost? Does it lead to more surgical complications? This is always a concern with neoadjuvant therapies. We've got someone in our clinic with a resectable lung cancer. If we mismanage that patient, we may lose the window for resection. So we always worry about delayed surgeries, canceled surgeries, more complicated surgeries. There have anecdotally been reports of increased perihilar fibrosis after neoadjuvant immunotherapy. Wouldn't that lead to longer, more complicated surgeries? And what we saw, frankly, was a bit surprising, for me. Surgery consistently easier, better in the experimental arm really across the board. The rates of going to surgery, completing surgery, 83% with nivolumab/chemotherapy, versus 75% with chemotherapy. So more patients going to surgery, fewer canceled surgeries. If we look at the type of surgery, minimally invasive surgery rates 30% with nivolumab/chemotherapy, [and] 22% with chemotherapy alone. Conversion to open thoracotomy was more common in the chemotherapy alone at 16%, the additional nivolumab 11%. And the complete R0 resection was achieved in 83% with nivolumab/chemotherapy, 78% with chemotherapy alone. Adverse events delayed surgery in six patients getting nivolumab and chemotherapy. It's important to watch that. But it was nine patients in getting chemotherapy alone. And if we look at the duration of surgery, and certainly there are many confounders in a statistic like this, but the surgery was shorter with nivolumab, certainly not lengthening the surgery. 184 minutes for nivolumab/chemotherapy, 217 [minutes] with chemotherapy alone. So these data are very reassuring to someone with a potentially resectable cancer. And I think that when I take a step back and look, maybe these results do make sense. Maybe this is what I should have expected. If we give a treatment that is more effective, that is a higher response rate, it works better. Those patients are less likely to have progressive disease, and the surgery should be more straightforward if there's less cancer to resect. So the CheckMate-816 surgical data, we've been waiting for this shoe to drop, and it was very reassuring. Perioperative immunotherapy is going to be an important part in the management of stage II/III non-small cell lung cancer in the years to come. Now going forward, we'll need to compare these adjuvant and neoadjuvant approaches and the relative merits of either strategy, but these results, I thought, were very reassuring. ASCO Daily News: Excellent. Well, moving on to the PACIFIC trial, Abstract 8511, this study reported improvements in 5-year overall survival and progression-free survival for unresectable stage III non-small cell lung cancer. What are your takeaways from this study? Dr. Stephen Liu: Sure. The PACIFIC study is a randomized phase III trial that's really set our standard of care for unresectable stage III locally advanced non-small cell lung cancer. This is a group where our standard of care, historically, has been concurrent chemoradiation, with the goal of cure, though, unfortunately, not necessarily the expectation, with recurrence rates quite high. We saw years ago the addition of 1 year of durvalumab improved progression-free survival, then ultimately improved overall survival compared to placebo. This was a fairly straightforward study. It enrolled unresectable stage III non--small cell lung cancer after chemoradiation, who did not have evidence of progression after completing therapy, to receive 1 year of durvalumab or placebo, a 2 to 1 randomization. The results markedly positive, leading to U.S. Food and Drug Administration (FDA) approval and really our new standard of care. These are long-term survival data, and it was presented by Dr. David Spigel. These are really important. Immunotherapy, the whole appeal of the strategy is the durability, the induction of memory T cells, meaningful long-term survival. Will this increase the rate of cure really is what we're going for. And when we saw the survival benefit with durvalumab, we knew that we were curing more patients. Long-term follow up is important to make sure that we don't have late recurrences, that we really are curing and not just delaying a recurrence for some patients. And in this analysis, with a 5-year follow up, we see durvalumab improve the median survival from 29 months with chemoradiation alone to 48 months with the addition of durvalumab. That's a hazard ratio of 0.72, 28% reduction in the risk of death, pretty substantial. That 5-year survival rate was 43% versus 33%. And importantly, these were very similar to the 4-year data that were presented by Dr. Corinne Faivre-Finn at World Conference in Lung Cancer, really very little drop off between year 4 and 5. And we refer to that as flattening of the tail, where the events are early, and at some point, they kind of stop happening. It's really what we want to see. While survival is what we hone in on, in an abstract like this, we also need to pay attention to progression-free survival (PFS). And the PFS rate at 5 years was 33% with durvalumab, versus 19% with chemoradiation alone. So 33% with no evidence of progression at 5 years. And if you are cured from lung cancer, then you can't have progression. So one in the three patients with no progression at 5 years, I think, is very reassuring, that PFS hazard ratio of 0.55. So prior to ASCO21, durvalumab was our standard of care. Now we just have longer term follow up to really solidify that choice. These are important data for patients and families to set expectations right, but our clear standard. Still, though, room for improvement in that 5-year PFS rate of 33%. We would like to see that higher, and ongoing strategies hopefully will help push that up. ASCO Daily News: Excellent. Some great survival data in the PACIFIC trial. Well, Abstract 9007 sparked a lot of interest as well. This is an expansion study of patritumab/deruxtecan in patients with EGFR-mutant non-small cell lung cancer. That's a difficult drug to pronounce, so I'm sure you'll do a better job. What can you tell us about this? Dr. Stephen Liu: Well, yeah, all these antibody drug conjugates do have tricky names, and so they are kind of fun to say. So patritumab/deruxtecan is a HER3 antibody drug conjugate. I suspect it will be better known as HER3-DXd, a little easier off the tongue. This was a study that looked at this agent in patients with EGFR-mutant non--small cell lung cancer after TKI therapy. And when we turn our attention to targeted agents, we have really transformative drugs with very wide therapeutic windows, little toxicity, very high efficacy, [and are] really game changers in patients with driver positive non--small cell lung cancer. But as we know, these treatments aren't cures. And we do expect resistance to osimertinib. The third generation TKI has been pretty heterogeneous. And once patients progress in osimertinib, the next standard therapy really is chemotherapy. And there's a bit of a drop off, with more toxicity, [and] less efficacy overall. So this remains an unmet need. Many studies are looking at different strategies there. We've seen the addition of MET inhibitors if MET is amplified for certain subtypes, RET, BRAF, for example, the addition of the targeted agents. This study, Abstract 9007 presented by Dr. Pasi Janne, looked at the HER3-DXd antibody drug conjugate. So patritumab/deruxtecan has a monoclonal antibody targeting HER3, a proprietary linker, and then a topoisomerase 1 warhead. And this was a phase I study that looked at 57 patients with EGFR-mutant lung cancer after TKI therapy mostly, but 90% were coming off of osimertinib. And what we saw, I thought, was very encouraging. This is a small, early study. These are very selective patients. But the response rate here almost 40%, disease control rate 72%, and the median progression-free survival with monotherapy of patritumab/deruxtecan was 8.2 months. These numbers may change as the studies get larger, but there's a clear signal of efficacy for patients who'd received chemotherapy before and then moved on to patritumab/deruxtecan. The response rate didn't really drop off, 37%. So even those that were more heavily pretreated, we're seeing a clear signal with response rates that really are higher than chemotherapy. What was, I think, most important, we saw efficacy of patritumab/deruxtecan across multiple different mechanisms of resistance. And so it wasn't one biomarker select. It really was active, very versatile agent. And really, I think that's what we need. While biomarker-driven resistance will be something we always hone in on and try to focus, we do need something that's much more versatile for rapid implementation. And this is having a lot of potential. [It was] very well tolerated. If we look at treatment-emergent adverse events, only one person stopped from a TEAE. Only 4% stopped due to TEAEs, so very well tolerated treatment. Response was also durable. One response listed was after 4 years of therapy, and so the potential for long-term disease control, long-term responses. So clearly an active drug. This is an area where we need a lot of drug development. Well tolerated, only 4% stopping due to adverse events and a nice signal of activity. Our next steps will be to make this a larger study to look in more patients to really hone in on the mechanisms and where this really is working. Can we widen that therapeutic index? And can we look at combinations? Is there a role to continue TKI with this, maybe for better CNS coverage or activity? That's what we'll see in the years to come. ASCO Daily News: Excellent. Well I'd like to ask you about a trial that you were involved in, the ARROW trial, Abstract 9089. Can you tell us about this impactful study? Dr. Stephen Liu: Yeah, sure. The ARROW trial is a study that I've been a co-investigator on for many years. This was presented by Dr. Giuseppe Curigliano. And this looks at a RET inhibitor called pralsetinib, originally when we first got involved called BLU-667. RET fusions are present in about 1% of non- small cell lung cancer. These are important events, because we know from other studies, such as the immunotarget registry led by Julien Mazieres,  that RET-positive lung cancers don't seem to respond as well to immunotherapy. However, in the past, the kinase inhibitors, the targeted agents we had the targeted RET, weren't very good. They had response rates around 30%, 40%, a lot of toxicity. These are drugs like vandetanib, cabozantinib. With the introduction of selective RET inhibitors, we've seen striking efficacy and much better tolerability. And we now have two approved RET inhibitors in this space--selpercatinib and pralsetinib--both receiving FDA accelerated approval based on their respective single arm studies. What we saw at ASCO 2021 from Dr. Curigliano was an update on the RET fusion positive lung cohort of ARROW. Again, this was a phase I/II trial looking at pralsetinib given at a dose of 400 milligrams by mouth once daily. We look at the patients with RET fusion-positive lung cancer. Now we just have longer follow up and more patients. And overall, the cohort exceeded 200 patients, so 216 patients for a pretty rare driver. And the response rate, 69%, very durable. The duration of response, 22 months. So really solidifying the efficacy and confirming the role in patients with RET fusion-positive lung cancer. If we break those data down a little bit, patients who had prior chemotherapy, which was 125 patients, response rate was 62%. The disease control rate, 91%. These responses are quick. The median time to responses is 1.8 months, so really that first scan. And that's what we see with targeted therapy. And we look at these waterfall plots, and I encourage you to take a peek at that. It's exactly what we want to see, the vast majority of patients, almost all patients, with some reduction and some with a quite substantial reduction. Again, the disease control rate after chemo was 91%. So really, the waterfall plot has that look that we seek for effective targeted therapy. The outcomes were even better in the first-line setting. Response rate originally 79% as first-line therapy. But the way the trial was originally written, it only included frontline patients who weren't eligible for chemotherapy for whatever reason. So that's going to be a more selective cohort. That was changed with an amendment. And once that was removed for people that were eligible for whatever frontline therapy you wanted to give, really our real world first line cohort, the response rate was 88%, disease control rate of 96%. So to think of a response rate in almost 90% of patients really gives us that confidence we want when we have a driver that we detect when we start a new agent. We're very confident that we're going to see efficacy in these drugs, very well tolerated, very few patients stopping due to a adverse event. A disease control rate of 96% in that first-line setting gives me the confidence to really use this in the first-line setting. ASCO Daily News: Absolutely. Well, as you know, the Annual Meeting this year focused on equity in cancer care. And there were a number of studies presented in the lung cancer space. I just wanted to get your thoughts on how this issue was addressed at the Annual Meeting in the lung cancer setting. I'm thinking of Abstract 9005 that looked at racial disparities. What are your thoughts on this issue? Dr. Stephen Liu: Yeah, this was an important abstract, I think. And the theme that Dr. Lori Pierce set of equity really was met by several different abstracts and was a recurrent focus for many important and really overdue discussions. Abstract 9005 was presented by Dr. Debora Bruno, and this really looked at disparities in biomarker testing. And we just talked about advances for EGFR-mutant lung cancer for RET fusion-positive non--mall cell lung cancer. We have many, many more, but we can only offer these agents if we know the target is present. And if we don't do proper biomarker testing, our care will not be optimal. If we don't know the molecular genotype of the cancer, we can't treat it properly. We are just guessing, and we're much more likely to deliver an ineffective therapy. We are potentially making subsequent therapies more dangerous. Knowing the right biomarker is critical to the proper management of non-small cell lung cancer. And if we don't have that, the outcomes will not be as good. The testing really is critical for the management of lung cancer. And what we saw from this abstract was there are disparities in how patients with non-small cell lung cancer are being tested, which simply isn't acceptable. This was a retrospective analysis that looked at Flatiron data, recent data, 2017 to 2020, a large data set, almost 15,000 patients with non-small cell lung cancer. Demographics were 66% white, 9% Black. If we look at biomarker testing specifically, patients who were Black were less likely to be tested, less likely to have proper biomarker testing, 73% versus 76%, less likely to have full next generation sequencing with a 10% difference, and less likely to get tested early. We know that testing really influences treatment from the jump right away. And if we don't have that information, our outcomes won't be as good. Our Black patients weren't being tested properly, weren't being tested in a timely manner. And more data showed that clinical trial participation was also decreased among Black patients, 4% involvement for white patients, 2% with Black patients. And these were actually very similar to what we saw in Abstract 9001 that was presented by Dr. Akinboro from the FDA. And that looked at patients who'd received chemoimmunotherapy. This was a pooled analysis looking at different PD-L1 cohorts. And what was noted on the demographics is that in the phase III registrational landmark studies, Black patients only represented about 2% of patients there as well. So strikingly similar numbers and a gross under-representation. It really is inexcusable and something we need to address. And we need to correct, because this is showing that our care is simply not up to par.  Trial participation is how we move the field, but many cases, especially in lung cancer, a field that moves so quickly, a clinical trial often represents the best possible option. And Black patients simply aren't enrolling in studies. And I think some of the disparities in clinical trial participation likely reflect some of the disparities in clinical trialists. And I think that if we continue to improve diversity in our workforce, in our oncology subspecialty, that'll be an important step into rectifying this. But this is something we need to look at critically. We need to assess all of our processes and think how we can do better today, and not tomorrow. ASCO Daily News: Absolutely. Thank you so much, Dr. Liu, for highlighting these really critical points and sharing your valuable insight on all of these impactful studies in lung cancer. Thank you so much. Dr. Stephen Liu: My pleasure. Thanks for having me. ASCO Daily News: And thank you to our listeners for joining us today. If you enjoyed this episode, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclosures: Dr. Stephen Liu Consulting or Advisory Role: Genentech, Pfizer, Lilly, Bristol-Myers Squibb, AstraZeneca, Takeda, Regeneron, G1 Therapeutics, Guardant Health, Janssen Oncology, MSD Oncology, Jazz Pharmaceuticals, Blueprint Medicines, Inivata, PharmaMar, Daiichi Sankyo/UCB Japan, BeiGene, Amgen, Turning Point Therapeutics, Elevation Oncology, and Novartis Research Funding (institution): Genentech/Roche, Pfizer, Bayer, Merck, AstraZeneca, Blueprint Medicines, Lilly, Rain Therapeutics, Alkermes, Bristol-Myers Squibb, Turning Point Therapeutics, RAPT, Merus, Elevation Oncology, and Erasca, Inc Travel, Accommodations, Expenses: AstraZeneca, Roche/Genentech, and MSD Oncology   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

**This episode was recorded before 3/1/2021. The game system used in this episode is no longer being played on current recordings of the podcast.** Previously, Pearl and Luca spent some time training with Sully at her home in the Podostroma Plains. As a reward for their efforts, Sully's Oranguru, Tang, taught some special new moves to members of The Cuddle Bunch and Teen Squad. A new day has come, and since our heroes are still ahead of schedule with their travel plans, Sully is taking them to see the Solar Cairn. How old is this mysterious monument? What secrets does it hold? And what the heck even is a cairn, anyway?? DM: Jonah M. Jackson Pearl: Sarah Katherine Zanotti Music: FoolBoyMedia - Video Game Land GlitchxCity - Team Rocket Battle Remix (v. I & II), Team Rocket Hideout Remix, Radio Tower Takeover! Remix https://www.youtube.com/user/GlitchxCity Braxton Burks & Materia Collective - Battle! Team Rocket Grunt, Team Rocket Strikes Back https://www.materiacollective.com/artist/braxton-burks Zame - Pokémon Colosseum Normal Battle Remastered https://www.youtube.com/user/ZameJack Rossini - William Tell Overture Kyle Preston - Rise, Fossils Sir Cubworth - A Fallen Cowboy Chris Haugen - Way Out West Topher Mohr and Alex Elena - Horses to Water Silent Partner - Stomping Grounds TGH - Beneath the Blaze DarkeSword - The Destiny Infinite ~Eevee~ Ectogemia - National Park ~Espeon~ TabletopAudio.com - Windswept Plains, Sun Dappled Trail, Barren Wastes, Desert Winds

Wie hat die die Serie ENTERPRISE lose Handlungs-Fäden verknüpft? Die 4. Staffel versuchte, in einigen Mehrteilern Handlungsbögen und Motive aufzugreifen und abzuschließen, um diese Prequel-Serie besser mit dem Rest des Star Trek-Franchises zu verbinden. In dieser Ausgabe beschäftigen wir uns mit dem Temporalen Kalten Krieg, der in der Pilotfolge der Serie eingeführt und in den beiden ersten Folgen der 4. Staffel ("Storm Front, part I & II") zu einem Ende gebracht wurde.

ARTIST: SISTER MAKI // TITLE: PRAYERS CAT. NR: DUB034 // GENRE: ROOTS REGGAE / DUB TRACKLIST: 01 - Prayer (Sister Maki) / 02 - Judgement in the Rain (Ras Tamano) 03 - 3x3 dub (Binghi-D) / 04 - Prayer Riddim / 05 - Judgement in the Rain Riddim New EP coming from the Land of the Rising Sun with Sister Maki on the Vocals. The Osaka reggae singer, known through her collaboration with Dub Cmd in 2020 on Way To Zion (Pt. I & II), returns with a new EP. This time she collaborates with some great artists from her homeland Japan. Produced by the multitalented Swe (producer, artist, event organiser, woodcrafter, Kette drum builder and landscape gardener), Prayers features Sister Maki, on the vocals, Ras Tamano from Nara the (member of the roots reggae band, Desanc and maker of reggae artists dolls) on the melodica and Binghi-D on the Kette Drum. CREDITS: Production & Riddims - Swe (JP) / Vocal & Lyrics (01) - Sister Maki (JP) / Melodica (02) - Ras Tamano (JP) / Kette Drum (03) - Binghi-D (JP) / Mixed & Mastered by Swe Rooting (JP) / Art Work by Mingalang

El 6 de mayo de 2021, en su página de internet Sputnik. Público la información sobre el estudio de la nueva vacuna Sputnik Light. La vacuna de dosis única Sputnik Light demostró una eficacia del 79,4% según los datos analizados tomados 28 días después de que se administró la inyección como parte del programa de vacunación masiva de Rusia. La tasa de eficacia se calculó en base a datos obtenidos de rusos vacunados con una sola inyección, que no recibieron la segunda por ningún motivo durante el programa de vacunación masiva entre el 5 de diciembre de 2020 y el 15 de abril de 2021. La tasa de infección entre los sujetos vacunados a partir del día 28 desde la fecha de la inyección fue solo del 0,277%. Durante el mismo período, la tasa de infección entre la población adulta no vacunada fue del 1,349%. Se utilizó la siguiente fórmula para calcular la eficacia de la vacuna: TIPANV- TIPAV ̳ 1.349%-0.277% ̳ 79.4% TIPANV 1.349% (TIPANV ) Tasa de infección entre población adulta no vacunada (TIPAV ) Tasa de infección entre población adulta vacunada El estudio fase I / II de seguridad e inmunogenicidad de la vacuna Sputnik Light ha demostrado que: 1-Sputnik Light puede provocar el desarrollo de anticuerpos IgG específicos de antígeno en el 96,9% de las personas el día 28 después de la vacunación; 2-La vacuna Sputnik Light provoca el desarrollo de anticuerpos neutralizantes de virus en el 91,67% de las personas a los 28 días de la inmunización; 3-La respuesta inmune celular contra la proteína S del SARS-CoV-2 se desarrolla en el 100% de los voluntarios en el décimo día; 4-La inmunización de individuos con inmunidad preexistente contra el SARS-CoV-2 con Sputnik Light puede provocar el aumento del nivel de anticuerpos IgG específicos de antígeno en más de 40 veces en el 100% de los sujetos 10 días después de la inmunización; 5-No se registraron eventos adversos graves después de la vacunación con Sputnik Light. REFERENCIA https://sputnikvaccine.com/newsroom/pressreleases/single-dose-vaccine-sputnik-light-authorized-for-use-in-russia/ https://sputnikvaccine.com/ ADAPTACION PARA AUDIO-OYENTES: Medicina en una página. ================================================ PODCAST CORONAVIRUS. COVID-19 Este es un podcast en el que desde el ojo de la ciencia. Aprenderemos del coronavirus y de la enfermedad covid-19. Recuerden al enemigo es mejor conocerlo. Para acabarlo. Esta es una producción de: Medicina en una página. medicinaenunapagina@gmail.com Dirección y Conducción: John Jarbis García Tamayo. Médico y cirujano, Epidemiólogo y Pedagogo Universitario. Portada: Gracias a Sam Balye por compartir su trabajo (foto-portada) en https://unsplash.com/. Música: https://www.youtube.com/audiolibrary/music?nv=1

Helena Lass on pühhiaater, Teadliku muutuse kunsti I-II praktik, õpetaja, uurija, lektor ja koolitaja vaimse vormi ning töökeskkonna heaolu alal. Lisaks on ta ka Lilleoru teadlikkuse õppekeskuse liige ja seal tegutseva Ingvar Villido õpilane. Lõpetanud on Helena Tartu Ülikooli arstiteaduskonna aastal 2004, spetsialiseerudes seejärel psühhiaatria erialale. Töötanud on ta lühiajaliselt ka Londoni lähistel Inglismaal. Alates 2013 töötab Helena eriarstina. Oma vaadetes lähtub ta teadvuse primaarsusest – teadmistest ja tehnikatest, mida tuntakse Teadliku Muutuse Kunstina. Positiivse vaimse tervise, ennetuse, töökeskkonna heaolu ja teadlikkuse teemal on ta artikleid lisaks Eestile avaldanud Inglismaal, Uus-Meremaal, USA-s, Kanadas, Indias, Lõuna Aafrika Vabariigis ja veel teistes riikides. Avalike esinemiste raames on alates 2013 aastast olnud arstide, personalijuhtide ja ettevõtjate ees. Helena suurim publik on siiani olnud Lätis – 500 inimest. Helena hobideks on joogateadus, aroomiteraapia ja disain. Ausad Mehed: www.chriskala.com www.ausadmehed.ee Facebook: www.facebook.com/podcastausadmehed/ www.facebook.com/chriskkala Vaata Helena tegemisi: http://helenalass.com

Series on I II and III John --- Support this podcast: https://anchor.fm/northlandbaptist/support

Fr. Aquinas Guilbeau joins us to talk about the Thomistic understanding of the virtue of Temperance.Scroll to the bottom of the page for the show transcript https://thecatholicmanshow.com/store/ (Check out our store and find TCMS stocking caps and hats)https://thecatholicmanshow.com/wp-content/uploads/2020/12/TCMS-Hat-Slider-2.png () https://thecatholicmanshow.com/wp-content/uploads/2021/01/IMG_5047.jpg ( ) ENJOY THE SHOW AND WOULD LIKE TO SEE MORE? SUPPORT TCMS, GET AWESOME THANK YOU GIFTS, AND HELP SPREAD THE WORD. http://www.patreon.com/thecatholicmanshow (Become a Patron! Over 40 interviews, a course with Karlo Broussard, a 10 part series on the domestic church, and free thank you gifts for supporting the show!) https://selectinternationaltours.com/catholicmanshow/ () Travel to Italy, the Holy Land, Scotland, or Europe. Take a Catholic pilgrimage cruise or mix in Faith and Food or Faith and Fitness. No matter where you travel with Select, you will be embraced by faith. All our trips feature daily mass, unparalleled access to sacred sites, local guides that speak your language, and excellent accommodations. We have been helping pilgrims put their feet in the places their faith began for over 30 years. We want to help YOU experience the fun and faith-enriching power of pilgrimage. https://selectinternationaltours.com/catholicmanshow/ (Click here) About our drink: Torabhaig https://www.torabhaig.com/single-malt-scotch-whisky/ (Single Malt Scotch Whisky) Torabhaig is another of the traditional farm steading-turned distillery projects cropping up across Scotland in recent years, though its output is significantly larger than many of its peers. Skye's second distillery is configured to produce a traditional island-style malt whisky – medium-weight and medium-peated with a long fermentation in wooden washbacks and plenty of copper interaction providing a fruit-forward spirit. Every drop of its spirit will be earmarked for bottling as a single malt to begin with, though expect to see some siphoned off for blending further down the line. About our gear: N/A About the Topic: [From the Summa] As stated above (https://www.newadvent.org/summa/2055.htm#article3 (I-II:55:3)), it is https://www.newadvent.org/cathen/05543b.htm (essential) to https://www.newadvent.org/cathen/15472a.htm (virtue) to incline https://www.newadvent.org/cathen/09580c.htm (man) to https://www.newadvent.org/cathen/06636b.htm (good). Now the https://www.newadvent.org/cathen/06636b.htm (good) of https://www.newadvent.org/cathen/09580c.htm (man) is to be in accordance with reason, as https://www.newadvent.org/cathen/05013a.htm (Dionysius) states (Div. Nom. iv). Hence https://www.newadvent.org/cathen/09580c.htm (human) https://www.newadvent.org/cathen/15472a.htm (virtue) is that which inclines https://www.newadvent.org/cathen/09580c.htm (man) to something in accordance with reason. Now https://www.newadvent.org/cathen/14481a.htm (temperance) evidently inclines https://www.newadvent.org/cathen/09580c.htm (man) to this, since its very name implies moderation or temperateness, which reason https://www.newadvent.org/cathen/03459a.htm (causes). Therefore https://www.newadvent.org/cathen/14481a.htm (temperance) is a https://www.newadvent.org/cathen/15472a.htm (virtue). About Our Guest: A native of Louisiana, Fr. Aquinas Guilbeau, O.P., entered the Dominican Province of St. Joseph in 2005. After several years of pastoral work in New York City, Fr. Guilbeau began doctoral studies in moral theology at the University of Fribourg, where he completed a dissertation on St. Thomas Aquinas's doctrine of the common good. In addition to his teaching, Fr. Guilbeau serves as senior editor of http://aleteia.org/ (Aleteia.org) (English edition). He is also the current prior of the Dominican House of Studies. The Catholic... Support this podcast

We are honored to say that this week our guest is the one and only Michael Berryman. A legend in the horror community with so many more films under his belt. Along side Jack Nicholson in the legendary One flew over the cuckoo's nest and the original Hills have eyes I & II, Michael has been apart of some amazing things in the film industry since the 1970s. We are digging into those movies plus working on Weird Science the 80s comedy classic, and appearing in a music video for Motley Crue. A favorite topic we cover today is working on The Crow with Brandon Lee, a story about what went wrong that day that took Lee's life and the scenes we didn't get to see because of the tragedy. It's all in this episode NOW and be on the look out for Michaels autobiography coming soon "It's all good"Be sure to check out https://michaelberryman.com/ afterward!Rock!

Describe a priori the relative Engel I success rates for pediatric epilepsy patients.Review the major procedural modalities for stage I / II epilepsy surgery.Discuss advances in less invasive intracranial mapping procedures for epilepsy.

一般頸痛就去診所電療、拉脖子全部做就對了？你只對了一半 徒手、運動、拉脖子是要看病人分類和屬於急性、亞急性、或慢性 車禍傷到脖子後頸圈戴起來！原來急性期帶個1-2週並非壞事 Timecode: 00:27 閒聊時間：聖派翠克節和美國疫情 06:19 萬眾期待的頸痛介入來了 07:06 Neck pain with mobility deficit分類的介入CPG推薦 13:26 病人突然脖子又痛起來是算急性期還是慢性期呢？ 17:15 胸椎徒手為什麼對這類病人這麼推薦？ 24:45 Elaine分享grade I-II徒手的觸感 25:42 Frank分享Gwen-Jull 線上演講對徒手止痛的想法 27:58 胸椎Clinical Prediction Rule (CPR) 31:38 頸椎Clinical Prediction Rule (CPR) 35:15 Neck pain with movement coordination impairment分類的介入CPG推薦 38:24 Frank覺得Stanley剛剛到底在供三小 歡迎到各平台追蹤或來信來訊跟我們提出疑問～ Facebook: https://www.facebook.com/2PROPT/ Instagram: https://www.instagram.com/2pro_pt/ Email: 2propt@gmail.com 也可以在此收聽： Apple podcast: https://tinyurl.com/y97q7tms Spotify: https://tinyurl.com/ydavzqxu Google podcast: https://tinyurl.com/yd86pbcl YouTube channel: https://tinyurl.com/y82ewo5b Music by Elizabeth's Groove by Amarià @amariamusique Creative Commons — Attribution 3.0 Unported — CC BY 3.0 Free Download / Stream: bit.ly/elizabeths-groove Music promoted by Audio Library youtu.be/-MO-mrBlo5s Reference: Blanpied PR, Gross AR, Elliott JM, et al. Robertson. Neck Pain: Revision 2017. JOSPT 2017 47:7, A1-A83

EL CINEMASCOPE: podcast cultural dedicado al cine, donde revisamos y comentamos sin tapujos algunos de los grandes del celuloide. Desde Negra y Mortal abrimos este espacio dedicado al cine, con la colaboración de Paco Atero, Alba Prieto, Noelia Da Silva, Roser Ribas y con la presentación y dirección y producción a cargo de David “Dave” Esquius. Grabado y producido en los estudios “El RaNcHo”. Nymphomaniac Vol. I & II (2013) es un controvertido film del cineasta Lars Von Trier donde se aborda la ninfomanía des de primera persona a través de Joe, una mujer que cuenta su experiencia con el sexo des de su infancia hasta su madurez. Con un reparto de peso (Charlotte Gainsbourg, Stacy Martin, Stellan Skarsgård, Shia LaBeouf, Jamie Bell, Christian Slater, Uma Thurman, Udo Kier, Willem Dafoe y Connie Nielsen) y 240 minutos de cinta, es una de nuestras imprescindibles.

Nacionalinio vėžio institutas skelbia, kad Lietuvoje išgyvenamumo rodikliai susirgus storosios žarnos vėžiu išlieka vieni žemiausių Europoje. Tam didelę įtaką turi būtent ligos stadija – vėžys aptinkamas per vėlai. Tik 34 proc. visų storosios žarnos vėžio atvejų Lietuvoje nustatomi I-II stadijų, o 17 proc. pacientų iš karto nustatomas IV stadijos storosios žarnos vėžys.Šiems prastiems rodikliams įtakos daugiausia turi ne paveldimumas, o netinkamas gyvenimo būdas: sėdimas darbas, prasta mityba. Dėl to storosios žarnos vėžys, kasmet nusinešantis po kelis šimtus gyvybių Lietuvoje, laikomas vakarietiška liga. Prognozuojama, kad dėl netinkamo gyvenimo būdo sergamumo šia onkologine liga rodikliai tik augs. Storosios žarnos vėžio gydymas būtų kur kas sėkmingesnis, jei gyventojai dažniau naudotųsi prevencinėmis programomis, bet joms koją kiša pandemijos ribojimai, o kartu ir pačių pacientų baimės: baimė išgirsti vėžio diagnozę, baimė per tyrimą patirti skausmą, baimė, kad po diagnozės gyvenimas pasikeis negrįžtamai. Kaip iš tiesų atrodo storosios žarnos vėžio gydymas, ar visais atvejais reikalinga chirurginė operacija? Kaip po to keičiasi paciento kasdienybė?Laidoje dalyvauja: Kauno klinikų Onkologijos skyriaus vadovė, gydytoja chemoterapeutė doc. Rasa Jančiauskienė ir Nacionalinio vėžio instituto Bendrosios ir abdominalinės chirurgijos ir onkologijos skyriaus gydytojas chirurgas dr. Audrius Dulskas.Ved. Laura Adomavičienė

Seguramente extrañas las tardeadas de los Ochentas, (I/II) bueno pues aquí tienes un coctelito Rockero Ochentero y en español: Mecano, Hombres G, Los Enanitos Verdes, Miguel Mateos, Duncan Dhu, Caifanes, Olé Olé en fin la lista es bastante larga. Súbele al Volumen y gracias por compratir... DjFerPOP

In this episode, Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, provide their clinical perspectives on new data from ASH 2020 on nonmalignant hematologic disorders, with topics including:Use of mycophenolate mofetil plus corticosteroids vs standard corticosteroid treatment in patients with ITP from the phase III FLIGHT study Analysis of an ongoing phase I/II trial of rilzabrutinib reporting safety and efficacy in the long-term extension for adult patients with relapsed/refractory ITPNew data from the phase III HOPE-B study of etranacogene dezaparvovec gene therapy, using an AAV5-vector to deliver the Padua variant of the factor IX gene in patients with hemophilia B An update from the phase I/II CLIMB THAL-111/SCD-121 studies reporting safety and efficacy on the first 10 patients receiving CTX001 with at least 3 months of follow-upPrimary analysis from the phase III REACH3 trial evaluating ruxolitinib, an oral JAK1/2 inhibitor, in combination with steroids and calcineurin inhibitors, as a treatment for steroid-refractory or steroid-dependent chronic GVHDTop-line results from the phase II ROCKstar study of belumosudil, a ROCK2 kinase inhibitor, in patients with heavily pretreated chronic GVHDPhase I data from the GRAVITAS-119 study of JAK1 inhibitor itacitinib plus calcineurin inhibitors as prophylaxis treatment for acute GVHDPresenters:Hanny Al-Samkari, MDInstructorDepartment of MedicineHarvard Medical SchoolAttending Hematologist and Clinical InvestigatorDivision of Hematology OncologyMassachusetts General HospitalBoston, MassachusettsSujit Sheth, MDProfessorDepartment of PediatricsWeill Cornell MedicineNew York, New YorkMark A. Schroeder, MDAssociate Professor of MedicineDivision of OncologyDepartment of MedicineWashington University School of Medicine in St LouisSt Louis, MissouriContent supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc.; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc.; Novartis; PharmaEssentia Corp.; Seattle Genetics; and Takeda Oncology. Link to full program, including downloadable slidesets, and on-demand Webcasts:http://bit.ly/3tyQ9nG

Sometimes, rock and roll dreams can get waylaid, subdued, or even killed by the signing of the line which is dotted. This episode would take 1,000 hours if we only include black artists from the '40s, '50s, and '60s. And '70s, '80s, and '90s. And '00s and '10s. So I just focused on the easy-hanging fruit that is the people who ALSO profited from the hard work of black musicians to make their palatable caucasian crafting.    Adam VIII John Lennon "Roots" Commercial (1975)   What a shitty, washed-out picture. This gives you the idea that Morris Levy just wanted to fuck with Lennon to pay him back for his hubris. Devout (at the time) fans of Lennon like me were perplexed when the last track on "Walls And Bridges" was a strangely shoddy cover of "Ya Ya" with Julian Lennon on drums. Little did we know that that was John Lennon "fulfilling a legal obligation". Just like a junkie would. I don't think anyone would think of Morris Levy as anything but a very sleazy anti-art leech, but that little joke was probably the last straw. "What the fuck is this washed-up hippy doing, and does he know what I can do to him?" Did this whole thing sour Lennon on recording more music, and did he sense his own waning desire to compete with McCartney and use this whole sorry escapade as a good excuse to spend some time in Japan?  Lennon was as dishonest and immature as he was gifted, and we will never know for sure.  The insert. Almost as insulting as "The Wedding Album".  Marvin Gaye - Where Are We Going? (1972) I talk to you like you know at least something about popular music. If you don't, let me be the first to tell you that Marvin Gaye recorded an album AFTER "What's Going On" and BEFORE "Let's Get It On". "You're The Man" was intended as another socially conscious record like "What's Going On" (1971), but following the release of its lead single, the title track "You're The Man", [ed: and the lack of positive reaction to same] Gaye canceled its release. [ed: I like this record a lot.] This was in part due to the reception of the song, as well as the fact that Gaye's political views were different from those of Motown founder Berry Gordy. For these reasons, "You're The Man" was long considered a lost album. Marvin Gaye - You're The Man (Pts. I&II) (1972) Marvin Gaye - The World Is Rated X (1972) Lou Reed - Metal Machine Music (1975) Like The Beach Boys, Bob Dylan, etc., some artists tend to benefit from revisionist history. No, "Metal Machine Music" is not a deep, thoughtful cry for help from a misunderstood genius. This was nothing but a big "fuck you" to RCA, which is sad to me because there were so many more talented, interesting, and profound artists than Lou Reed, struggling for royalties, swimming against the tide of record comp.....wait. Maybe he had a point.  ...but it's STILL not as bad as "Having Fun On Stage With Elvis". Badfinger - Apple Of My Eye (1973) Lookie here.  Badfinger - Get Away (1973) So you all know the struggles that Badfinger enjoyed with Stan Polley, who once managed one of my favorite singers, Lou Christie. But Badfinger also suffered under the weight of the lethargic promotion afforded them by The Beatles and Apple Records. This was THEIR Contractual Obligation album, and it's not bad at all. Guys that talented could never turn in a clunker.  From Loudersound:  (In 1973) Apple was in disarray, but Badfinger – by far the label’s most successful artists after The Beatles – had further cause for complaint. Their original contract, drawn up in the days when Apple was living up to its fair-minded (i.e. hippy) ideals, offered a generous artist royalty of 5 percent, with Apple also paying for all recording and promotion expenses. Now, with legendary US tough guy Allen Klein running the company, the band were being asked to not only take a reduced royalty rate but also to pay recording costs. George Harrison, for one, was devastated at the loss from the label of a group he held dear, and allegedly (and uncharacteristically) confronted Bill Collins [ed: their manager since 1966) and said: “You guys fucked us after we did all that work for you.” Collins retorted that they had been unable to speak to their former champion directly (an accusation that rings true with all the superstar retinue surrounding the former Beatle), let alone with the formidable Klein. In retrospect, Badfinger’s departure marked the beginning of the end of Apple as anything other than a ‘vanity’ label for John, Paul, George, and Ringo. But the inevitable payback was Apple issuing Ass (as the 1973 album ended up being rather unflatteringly called) as a spoiler three months ahead of the band’s debut for their new label. As it transpired, Ass would be the final non-Beatles album to appear on Apple (it reached No. 122 in the US). One track, Pete Ham’s Apple Of My Eye, was a genuinely fond farewell to their former paymasters, and he contributed only one other; much of the music was written by Joey Molland, which gave it a different feel. Al Steckler, the man who had given Badfinger ‘their’ gold disc in New York City, was later incredibly revealing to Stefan Granados, author of the invaluable Apple history Those Were The Days (Cherry Red Books) when he outlined the contract Badfinger signed with Warner Brothers. A band at the peak of their powers, with a track record of US success and the Beatles’ imprimatur, might have thought their next record deal would set them up for life. Not so. The advance, which looked good on paper, was $2 million for, Steckler told Granados: “something like six albums. After they signed, Bill Collins and Pete Ham told me what the advance was and I figured it out for them. When you deducted the cost of the albums they had to pay for, deducted Polley’s cut, and split the money between Collins and the four guys in the group, it came out to nothing… $60,000 apiece per album. They’d really thought they were millionaires. They looked at each other and realized that I was right and that it was too late to do anything about it. Peter had this horrible look on his face… it was the last time I saw him.” Badfinger - Timeless (1973) Bonzo Dog Band - King of Scurf (1971) Neil Innes wrote music for Monty Python and starred in "All You Need is Cash" with Eric idle. He was brilliant and he wrote songs that you know but don't know that it was him. I never liked this group, but as I mentioned in my show, they were in Magical Mystery Tour. These songs were recorded in 1971, a few years after they broke up. But the United Artists label pointed the Fickle Finger of Fate at the boys, and we have this.  Bonzo Dog Band - The Strain (1971)  Bonzo Dog Band - Bad Blood (1971) ELP - Memoirs of an Officer and a Gentleman (1978) The Mamas and the Papas - Blueberries For Breakfast (1971) Like the Bonzos, they were gently reminded by the bean-counters at Dunhill that there was some unfinished business. So they created this. Again, not that bad!  The Mamas and the Papas - Lady Genevieve (1971) For a drug-addled, amoral daughter-fucker, John Phillips sure wrote a lot of songs about his wife.  The Mamas and the Papas - Pacific Coast Highway (1971) The Mamas and the Papas - People Like Us (1971)

Estamos de aniversario. A iniciativa dun grupo de estudantes de arquitectura, o 3 de novembro de 1995 quedou legalmente constituida Arquitectura Sen Fronteiras Galicia. Arquitectos Sen Fronteiras daquela, que o cambio de nome chegaría máis adiante. Literalmente manifestaban: Esta asociación gallega surge desde la Escuela de Arquitectura de A Coruña entre estudiantes y jóvenes arquitectos, por la inquietud de dar respuesta a las necesidades de carácter técnico que aparecen en las zonas marginales y de escasos recursos, dando salida de forma diferente a los conocimientos adquiridos en la carrera. Unha conversa con protagonistas de antes e agora recordando a traxectoria que nos trouxo ata aquí. Ligazóns de interese: 1995 Arquitectos Sin Fronteras. Principios. Preceptos Memorias de Actividades ASF Galicia dende 1995 ata agora Créditos Todas as cancións incluídas neste episodio e no momento da súa publicación distribúense baixo licenza Creative Commons. A Vida, Maya Solovey, álbum Maya Solovéy, I:II Subscrición Feed | iTunes | iVoox | Spotify Contacto gtcomunicacion.gal[arroba]asfes.org | @ASF_Habitando | Facebook

#Devavan with #ACourseInMiracles - #ACIM about the power of forgiveness applied as power of questioning and reasoning with conceptual thought forms. It is your own personal experience that secure you #safety, #freedom and #peace-of-mind.We share the words of Jesus Christ in A Course in Miracles with the Lessons 333 of the Workbook and parts in Chapter 1-I-II of the Textbook of ACIM"Conflict must be resolved. It cannot be evaded, set aside, denied, disguised, seen somewhere else, called by another name, or hidden by deceit of any kind, if it would be escaped. It must be seen exactly as it is, where it is thought to be, in the reality which has been given it, and with the purpose that the mind accorded it. For only then are its defenses lifted, and the truth can shine upon it as it disappears...." Also in full length as YouTube-Video #DevAvan: https://youtu.be/8tA5u33oDVg

FDA 批准治疗Cushing综合征的新药BMJ 妊娠期糖尿病患者16年后的2型糖尿病患病率比对照组高8.5倍Science Advance 可监测血糖、治疗糖网的隐形眼镜奥西卓司他（osilodrostat）奥西卓司他（osilodrostat）是一种新型的口服11‐β‐羟化酶和醛固酮合成酶抑制剂，可以直接阻断肾上腺皮质醇合成。2020年3月，FDA批准奥西卓司他上市，用于治疗库欣综合征，这是FDA批准的首个口服11‐β‐羟化酶抑制剂。《LINC3研究：奥西卓司他治疗库欣氏病的多中心、双盲、随机停药的III期临床试验》Lancet Diabetes Endocrinology，2020年8月 (1)LINC 3研究是一项前瞻性、多中心、开放标签、III期研究，旨在研究奥西卓司对库欣氏病治疗的安全性和有效性。研究共入组137人（平均年龄41岁、3/4为女性、未接受过垂体切除手术或接受过垂体切除手术但未治愈、24小时皮质醇>1.5*ULN）。研究采用双盲随机停药，包括四个期：（1）所有参与者服用开放标签的奥西卓司他直到第12周，每2周调整一次剂量直至30mg bid；（2）第13-24周，继续使用奥西卓司他；（3）26周开始，双盲、随机停药8周；（4）35-48周，所有患者开放标签的奥西卓司他直到研究结束。研究发现在，第34周，与随机停药组29%的患者相比，随机服药组86%的患者保持完全缓解状态。137例患者在第12周后完全缓解，滴度没有上升。结论：每天两次奥西卓司快速降低了平均24小时皮质醇浓度，同时改善了临床症状。2型糖尿病的预防2型糖尿病的高危人群包括：年龄≥45岁，有妊娠期糖尿病病史，BMI≥25kg/m2，一级亲属有糖尿病，久坐的生活方式，高血压高血脂。预防糖尿病的发生主要通过：锻炼和减重，戒烟或服用二甲双胍。其他用于预防的糖尿病的药，如利拉鲁肽、比格列酮、阿卡波糖、维生素D等，尚有争议。《荟萃分析：维生素D对糖尿病发病率的影响》Journal of Clinical Endocrinology and Metabolism，2020年8月 (2)这项荟萃分析的目的是平均25-羟基维生素D（25[OH]D）血液水平低与胰岛素分泌受损、胰岛素抵抗增加和2型糖尿病发病率增加相关。研究者对9项随机对照试验进行了荟萃分析，涵盖43,600名参与者，随访至少一年。在接受较大剂量维生素D（≥1000IU/d）的、糖尿病前期的、人群中，2型糖尿病的发病率较低（相对风险比 0.88），这一结果勉强达到统计学显著性。在接受较小剂量维生素D（

主播 ｜ 李志明 嘉宾 ｜ 姜乙在文学作品的传播中，翻译是不可或缺的一环，然而与诸多姓名如雷贯耳的作家不同，译者往往是隐形的。有的翻译或许是一种语言到另一种语言简单的对应，然而本期节目嘉宾德语译者姜乙认为，文学翻译是跟作品、作家、以及原文语言的一种超乎寻常的亲近。姜乙本科期间学习的方向是歌剧演唱，现在也并不是一位全职译者，她是一个慢性子的人，一篇全文仅五万字左右的《悉达多》就花费了她一年的时间进行翻译，因为她需要不断地思考与改进，这是她与作品之间的“对抗”，也是她认为翻译的乐趣所在。在本期节目中，她将与主播李志明聊聊她眼中的翻译和她眼中的黑塞。|Song List| 01.Marlene Dietrich - Ich bin von Kopf bis Fuß auf Liebe eingestellt02.San Francisco Symphony / Igor Fyodorovich Stravinsky / Michael Tilson Thomas - Component 1 - The Rite of Spring: Part II - the Sacrifice: Mystic Circles of the Young Girls03.The Munich Philharmonic Orchestra / Karl Richter - Chor “Kommt，ihr Tochter，helft mir klagen” (chor I/II ) mit Choral: O Lamm Gottes unschuldig”(Knabenchor) 04.San Francisco Symphony / Igor Fyodorovich Stravinsky / Michael Tilson Thomas - Component 1 - The Rite of Spring: Part I - Adoration of the Earth: Introduction05.Helmut Walcha - Buxtehude: Passacaglia In D Minor, BuxWV16106.Víkingur Ólafsson / Halla Oddný Magnúsdóttir - Gottes Zeit ist die allerbeste Zeit, BWV 106:1. Sonatina (Transcr. for Piano Four Hands by György Kurtàg)

Previously, Pearl and Luca left Spudnik and decided to spend a bit more time exploring the Misty Isle. After getting slapped by a fish and catching some new Pokémon friends, they left the island to finally head home and go to bed. But with the door to the cottage mysteriously unlocked, things may not be as peaceful as they seem. What's going on inside the Salvatore lake house? Are the Lake Bois safe inside? Could this personal day be any less restful?? DM: Jonah M. Jackson Pearl: Sarah Katherine Zanotti Music: FoolBoyMedia - Video Game Land, Dramatic Scroller GlitchxCity - Team Rocket Hideout Remix, Team Rocket Battle Remix v. I & II, Hoenn Gym Leader Remix, Diamond and Pearl Cyrus Battle Remix, Red and Blue Lavender Town Remix v. II, Sinnoh Gym Leader Battle Remix, Johto Ice Path Remix Visager - Eerie Mausoleum, Miniboss Fight, Dark Sanctum Boss Fight, Sunset Over the Treetops TabletopAudio.com  - Lakeside Camp, Mansion: Night, Existential Dread, Shadowfell, Hermit Hut, Ghost Town, Quiet Cove

On today's show we speak with artist, musician, singer, songwriter, sculptor, designer and Renaissance man Ramiro Fauve. He talks with us about his varied and diverse career, his family and how he keeps doing what he does.  On October 6, 2020 his latest HIT album 'Where Rivers Cross Vol. I&II' drops. Make sure to pick it up!   To keep up with everything that he is up to, follow him on the internet at: ramirofauvemusic.com and on IG at: @ramirofauvemusic   Also on today's show we speak with attorney turned musician Erick Beau. Erick shares with us how he was able to come back to his first Love, music, after a long and distinguished career as an attorney.  In these crazy pandemic times Erick has taken what we all take for granted, the ability to come home, and has written a poignant but uplifting song about it called 'Coming Home'. Erick wrote this song based upon his experience of being stranded in Europe when the pandemic hit. From that moment on he realized that 'Coming Home' will not be the same for quite some time. Get his latest HIT song 'Coming Home' NOW! Pick it up from your favorite streaming service. Keep a look out for his HIT album 'What It Takes' dropping in May of 2021. To keep up with everything that he's up to, follow him on the internet at: Erickbeau.com and on IG at: @erickbeau1    Thank you for listening and follow us on IG at: @thebigfatjoeyshow

05/10/2020Thin End of the WedgeEpisode 1: Laith Hussein: Tell Harmal, heart of EshnunnaLaith Hussein talks about a key centre in the kingdom of Eshnunna. Eshnunna was one of several rival kingdoms fighting for supremacy in Iraq about 4000 years ago. What was found, and what work is being done? 3:06 about the site of Tell Harmal. Where is it? How big is it? When was it excavated? What was its ancient name?7:54 what ancient texts have been found there?13:01 how the archaeological remains and texts relate to each other. The production of huge numbers of bricks.15:54 what language are the texts in? And what do they talk about?17:36 what do they tell us about life in ancient Iraq?21:00 any plans for new excavations?Music by Ruba Hillawi Website: http://wedgepod.orgYouTube: https://www.youtube.com/c/WedgePod Email: wedgepod@gmail.com Twitter: @wedge_pod Patreon: http://Patreon.com/WedgePod The article Dr Laith mentioned is: "Bauplanung und Administration in altbabylonischer Zeit: ein Tonbullen-Archiv aus Tell Harmal (Shaduppum)", in Kaskal 9 (2012), pp. 3-29A brief report on the 1997-1998 excavations is available in English. The Iraqi scholars Dr Laith mentions as having worked on tablets from Tell Harmal are:Basima Jalil Abed, Unpublished Cuneiform Texts from the Old Babylonian Period in the Iraq Museum. Masters dissertation, Baghdad University (in Arabic). 1998Khalid al-A’dami, Some Old Babylonian Letters in the Iraq Museum. PhD dissertation. 1971Abdulkarim Abdullah Ahmed, Old Babylonian Loan Contracts in the Iraq Museum from Tell al-Dhiba’i and Tell Harmal. Masters dissertation, Baghdad University (= OBLC). 1964Saad Salman Fahad, Cuneiform Texts from the Old Babylonian Period, Diyala Region, Tell Harmal. Masters dissertation, Baghdad University (in Arabic). 1996Ahmad Hamid Majeed, Studies of Unpublished Old Babylonian Cuneiform Texts from the Diyala Region, Tell Harmal. Masters dissertation, Baghdad University (in Arabic). 1990 Ridha al-Hashimi, Some Old Babylonian Purchase Contracts in the Iraqi Museum from Harmal and Dhiba’i (OBPC). Masters dissertation, Baghdad University (in Arabic). 1964Menshed Mutlaq Menshed, Unpublished Cuneiform Texts from the Old Babylonian Period, Diyala Region, Tell Harmal. Masters dissertation, Baghdad University (in Arabic). 1997 Ahmad Kamil Muhammed, Unpublished Old Babylonian Letters in the Iraq Museum. PhD dissertation, Baghdad University (in Arabic). 1996Amir Suleiman, A Study of Land Tenure in the Old Babylonian Period with Special Reference to The Diyala Region, Based on Published and Unpublished Texts (= SLTOB). PhD dissertation, University of London. 1966Amir Suleiman, Harvest Documents and Loan Contracts from the Old Babylonian Period, Sumer 34/I-II (1978), pp. 130-138

The incredible events at Fatima happened 100 years ago, but as of today, we remain mystified.  Was it the Virgin Mary?  Or a UFO?  Expert and Filmmaker L.A. Marzulli digs deep to find the truth! L. A. Marzulli is an author, lecturer, and filmmaker. He has penned twelve books including The Nephilim Trilogy which made the CBA best sellers list. Based on his work on the trilogy, L.A. received an honorary doctorate from his mentor Dr. I. D. E. Thomas, who was the Provost at Pacific International University. He was also honored with the Gold Medallion award from Chuck Missler at the K-House conference in 2014. His book series On the Trail of the Nephilim vols I & II are full-color, over-sized volumes which reveal startling evidence of a massive cover-up of what he believes to be the remains of the Nephilim, the giants mentioned in the Bible.  He is the producer and director of two films on the events at Fatima.

The doctor is in the house! Dr. Jade Teta's specialty is "integrative endocrinology." It's the study of hormones & metabolism. Most of his career has been helping the most difficult metabolic cases lose weight. Jade has a license in California & Washington State and can prescribe all drugs except schedule I & II. He is not opposed to pharmaceuticals and does use them, he just prefers to lean on lifestyle change and natural approaches first. He is also an author. In his field of medicine they have a principle called Docere. It means "doctor as teacher." That's what he spends most of his time doing now; teaching through writing. He writes books and creates online educational products on metabolism, fitness & personal development. He teaches in three distinct areas; mind, muscle and metabolism.   In this episode, you’ll learn: Why a doctor chose podcasting to grow his practice What it means to be a next level human  How podcasting brings us closer together as humans How Dr. Jade uses podcasting as a key component to his business, writings, and collaborations with others And so much more!   Our courses on how to launch, grow, and monetize your podcast!  Level 101 by Operation Podcast Level 201 by Operation Podcast ~ You can find Dr. Jade on… Instagram https://www.instagram.com/jadeteta/  Learn more about being a Next Level Human at https://www.jadeteta.com  Listen to the Next Level Human podcast at https://www.jadeteta.com/blog?tag=podcasts    Connect with Chase! https://www.instagram.com/chase_chewning/  https://www.instagram.com/operationpodcast/    Learn how to successfully launch, grow, and monetize your own podcast at www.OperationPodcast.com and enroll in our Level 101 or Level 201 courses 

Previously, the Merrygold Riders faced off against the infamous cattle rustler Angel Mooney. After an intense battle, the nefarious ne'er-do-well teleported away with his only remaining Pokémon, a Xatu with shadowy powers. Unsatisfied with the disappearance of the criminal, the Merrygold Riders are scouring his hideout to see if they can find anything else to indicate where he might have gone. What happens now that Mooney's gone? Will they be able to get all the stolen Pokémon home? Are there pranks in store for our heroes?? DM: Jonah M. Jackson Pearl: Sarah Katherine Zanotti Ricky Jones - Adam LeGrave Music: FoolBoyMedia - Video Game Land GlitchxCity - Diamond and Pearl Pokémon League Lofi Remix, Johto Gym Leader Remix v. I & II, Johto Boss Remix v. II, Pokémon Tower Remix v. II Ozzed - About Ducks, Secret Treehouse Joseph Cash - Minigame Music Lobo Loco - Hey Go Audionautix - South of the Border Quincas Moreira - A Ghost Town Mini Vandals - Pale Rider Blues Topher Mohr & Alex Elena - Horses to Water ProtoDome - On the Origin of Species PokéNerd Scott - DaFarmSong TabletopAudio.com - Cavern of Lost Souls, The Underdark, Antiquarian Study, Lonesome West, Sun Dappled Trail, Windswept Plains

Theme: How to hear the Word profitably? #2 Point 1: I/II. Review of preparing and attending to hearing, Point 2: III. Apply yourself after hearing the Word

Please listen to Pastor Stephen Perumalla's sermon titled I Got The Joy (pt. III). If you have not listened to parts I & II yet, it is recommended that you do!

In this mid-week edition, identifying flawed research before it becomes dangerous, Michigan governor tells America to mask-up, Pfizer mRNA vaccine gets $1.95 billion from Warp Speed, preliminary phase I/II results of the ChAdOx1 SARS-CoV-2 vaccine, answers to listener questions. Hosts: Vincent Racaniello, Rich Condit, Kathy Spindler, and Brianne Barker Click arrow to play Download TWiV 644 (69 MB .mp3, 115 min) Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode US COVID-19 cases (NY Times) Identify flawed research before it is dangerous (NY Times) Mask up, America! (NY Times) $1.95 billion to Pfizer (NY Times) Phase I trial of Pfizer mRNA vaccine (medRxiv) Phase I/II trial of ChAdOx1 vaccine (Lancet) Rockefeller Foundation testing plan TWiV 640 on MedCram Letter drafts for $1 testing Letters read on TWiV 644 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

In this mid-week edition, identifying flawed research before it becomes dangerous, Michigan governor tells America to mask-up, Pfizer mRNA vaccine gets $1.95 billion from Warp Speed, preliminary phase I/II results of the ChAdOx1 SARS-CoV-2 vaccine, answers to listener questions. Hosts: Vincent Racaniello, Rich Condit, Kathy Spindler, and Brianne Barker Click arrow to play Download TWiV 644 (69 MB .mp3, 115 min) Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode US COVID-19 cases (NY Times) Identify flawed research before it is dangerous (NY Times) Mask up, America! (NY Times) $1.95 billion to Pfizer (NY Times) Phase I trial of Pfizer mRNA vaccine (medRxiv) Phase I/II trial of ChAdOx1 vaccine (Lancet) Rockefeller Foundation testing plan TWiV 640 on MedCram Letter drafts for $1 testing Letters read on TWiV 644 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

Series background Series started in 1987. Action RPG - meaning an action game where you gain XP to earn levels and there's a story. Loosely set in the time period of Roman conquest (100-150 BC) Sometimes compared to Zelda but Falcom had already been working on other action RPGs by then.  Falcom is primarily a PC developer, console ports are by many different companies US localization is all over the place Except for I&II the games are independent stories but there are fan service references to previous characters and events. However, the different localizations mean sometimes these are easy to miss because people and places have different names depending on who did the translation.      Common elements across the games Same lead character and sidekick (except for Ys Origin) High quality soundtracks Every soundtrack ever is on Spotify or can be bought from all of the various music sites  Rings that enhance your powers More levelling solves all boss fights   They literally give you places to grind (basement in ys II)   Typically not cutting edge in terms of technology, developer has never been interested in that Hudson's PC Engine CD ports are the big exception  Starting in the 2000s - trippy otherworldly final dungeons   Ys Book I & II Original bump mechanic Introduces the main character and sidekick First chapter revolves around final a set of lost books with the secrets of the world Half the game is one massive dungeon Second chapter is confronting the evil the books described. The second chapter is a typical JRPG format Go to a new town, solve their problems, go to the next town Imagine if like every time Nintendo released a new console they did a remake of Legend of Zelda Likely incomplete list of remakes: Master System (Sega), Famicom, TG16CD (Hudson), Sega Saturn (Falcom Classics), PS2 (Konami, Japan only), DS, PSP (Xseed), PC (Eternal & Chronicles), Android, iOS (dotemu)   Ys III - Wanderers Of Ys Switched to side scrolling format One main city - some future games also use the central city hub idea Probably the hardest in the series For many US gamers this is only Ys game they knew of until Y 6 or 8 - meaning people who only have popular consoles Debatable which port is best Has parallax scrolling, which people say is “not possible” on TG16.   Ys IV - Dawn Of Ys Return to bump mechanic Falcom designed the story and soundtrack but didn't develop it (they were working on LoH 3 around this time which unintentionally would change the course of their company) Super Famicom - Tonkin House  PC Engine CD - Hudson - which also has New Game+ for the first time in the series (and the last time for a while) No US release but high quality fan translations PS2 port by Taito If you liked I&II this is worth importing  My favorite of the 8/16-bit games   Ys V: Lost Kefin, Kingdom of Sand First attempt to change the attack style - it didn’t work out Visually resembles a Square game on SNES No US release but there are fan translations  PS2 port by Taito Regular and expert editions Only game in the series I didn’t finish because the controls are pretty bad, will probably try again Really good symphonic soundtrack album   Ys VI: The Ark of Napishtim Drastically improved combat compared to Ys V and subsequent games seem to be based off this engine PSP and PS2 releases in the US (ported by Konami) “VI” was dropped from the title in the US, probably because it had been over 10 years since Ys III was released in the US Shipwreck Major addition- weapon upgrade system   Ys: Oath in Felghana Beginning of the Toshiro Kondo era at Falcom - lowly script editor on this game then director then producer on the rest Second/current CEO of Falcom, originally hired because they liked his LoH 3 fan site Remake of Ys III in the Ys VI engine with more story Limited New Game+ feature (what you carry over depends on the difficulty + number of time you completed it) Even retro gamers will probably enjoy this more than the original version Not a  bad place to start if you want to play through the series but not go all the way back to the original games   Ys Seven PSP and PC Evolution of Ys VI engine and upgrade system Major addition - multiple playable characters with different attack types (slash vs stab vs crush) Special attacks and extra skills Main characters lose all their awesome gear when they are arrested at the beginning - I believe this is re-used in Ys IX Story wise - kind of a downer No New Game+ In terms of the series timeline, this is the last game (until IX)   Ys Origin Least story of any game in the series In terms of engine, kind of a step back - closer to Ys VI Short term stat boosts encourages you to not pause combat  2 different main characters with slightly different stories, unlock 3rd Most accessible for people who just want an action game with some leveling without a lot of story Limited Run games physical releases on PS4 and Vita   Ys: Memories of Celceta Remake of Ys IV but by Falcom this time Vita, PC and remake on PS4 Similar to Ys Seven with some elements that reappear in Ys 8 New additions - map completion, more emphasis on optional side quests Most complex weapon upgrade system, Ys 8 returned to a simpler one Upgrade system is a little overpowered, playing it again I forgot how easy the game is if you upgrade weapons Ret-cons a connection to Ys VI First signs of design influence with Trails series - Final dungeon is stylistically the same as the Trails in the Sky 3rd and Cold Steel II Actual New Game+ mode   Ys VIII: Lacrimosa of Dana “Trails of Ys” Same character notebook & event system from Trails of Cold Steel A couple minor characters copied from Trails in the Sky/Trails of Cold Steel Mishy Mascot from Trails series makes an appearance Fishing Return to Nintendo consoles (albeit by company doing the US port) shipwreck again Story revolves around finding survivors and building a town Dual lead characters in different times Probably the most accessible to new players Maybe my overall favorite in the series, although I could do without fishing  If you like Ys VIII you will probably like Tokyo Xanadu - although it is heavier in the story and character event aspects - roughly the same fighting engine (note: it was ported by Aksys and has the worst translation since the 1980s)   Ys IX: Monstrum Nox Coming to PS4 and Switch in 2021 Trying to avoid looking at it too much - seems similar to Ys 8 but with new character abilities Switch port again

In this episode, approval of an Ad5 vectored SARS-CoV-2 vaccine for the military in China, description and clinical trials of a Novavax vaccine joining Operation Warp Speed, prevalence of SARS-CoV-2 in Spain, shedding and transmissibility of the virus, and listener email. Hosts: Vincent Racaniello, Rich Condit, and Kathy Spindler Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode China approves COVID-19 vaccine for military (CNN) Ad5-vectored COVID-19 vaccine phase I results (Lancet) US pays $1.6 billion for Novavax vaccine (NY Times) CEPI awards $388 million to Novavax (Novavax) HHS on Novavax vaccine (HHS) Novavax phase I/II trials (GlobeNewswire) Prevalence of SARS-CoV-2 in Spain (Lancet) Shedding and transmissibility of SARS-CoV-2 (Nature) Letters read on TWiV 637 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

In this episode, approval of an Ad5 vectored SARS-CoV-2 vaccine for the military in China, description and clinical trials of a Novavax vaccine joining Operation Warp Speed, prevalence of SARS-CoV-2 in Spain, shedding and transmissibility of the virus, and listener email. Hosts: Vincent Racaniello, Rich Condit, and Kathy Spindler Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode China approves COVID-19 vaccine for military (CNN) Ad5-vectored COVID-19 vaccine phase I results (Lancet) US pays $1.6 billion for Novavax vaccine (NY Times) CEPI awards $388 million to Novavax (Novavax) HHS on Novavax vaccine (HHS) Novavax phase I/II trials (GlobeNewswire) Prevalence of SARS-CoV-2 in Spain (Lancet) Shedding and transmissibility of SARS-CoV-2 (Nature) Letters read on TWiV 637 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

Please listen to Pastor Stephen Perumalla's sermon titled As For Me And My House (Pt. III). If you have not listened to parts I & II yet, it is recommended that you do!  

In honor of Independence Day, Matt gives the story of the Vietnam War Memorial and the marvel of its simplicity. News Archives: British Pathe, CBS News, Iconic, Documentary Tube, Nuclear Vault, PBS, Battlefield Sources, ABC News, British Movietone, KTLA News, NBC News, WOR, Richard Nixon Foundation, AP Archive, ColdWarWarriors Soundtrack: "New England Air," by BOPD, from the album, "Old Paper Houses Soundtrack," 2013. Promoted by freemusicarchive.org. Licensed under CC BY-NC 3.0 (https://creativecommons.org/licenses/by-nc/3.0/legalcode). “Headwaters Instrumental,” by Chad Crouch from the album, “Field Report Vol. II: Reed Canyon,” 2019. Promoted by freemusicarchive.org. Licensed under CC BY-NC 3.0 (https://creativecommons.org/licenses/by-nc/3.0/legalcode). “Arrival of the Geese (Instrumental),” by Chad Crouch from the album, "Field Report Vol. II: Reed Canyon,” 2019. Promoted by freemusicarchive.org. Licensed under CC BY-NC 3.0 (https://creativecommons.org/licenses/by-nc/3.0/legalcode). “Seafoam,” by Chad Crouch from the album, “Atmospheric Piano,” 2019. Promoted by freemusicarchive.org. Licensed under CC BY-NC 3.0 (https://creativecommons.org/licenses/by-nc/3.0/legalcode). “Linen,” by Chad Crouch from the album, “Atmospheric Piano,” 2019. Promoted by freemusicarchive.org. Licensed under CC BY-NC 3.0 (https://creativecommons.org/licenses/by-nc/3.0/legalcode). “American Crow,” by Chad Crouch from the album, “Birds of Oaks Bottom: Piano Solos,” 2018. Promoted by freemusicarchive.org. Licensed under CC BY-NC 3.0 (https://creativecommons.org/licenses/by-nc/3.0/legalcode). “American Song,” by Maya Solovey from the album, “Maya Solovéy, I:II,” 2011. Promoted by freemusicarchive.org. Licensed under CC BY-NC-SA 3.0 US (https://creativecommons.org/licenses/by-nc-sa/3.0/us/legalcode).

On this episode, Michael & Jack celebrate the life and music of Billy Joel bassist Doug Stegmeyer. Known as The Sergeant, Doug played bass in the Billy Joel band from 1975 which he joined for the Streetlife Serenader tour and continued on through the end of The Bridge Tour in 1988. We discuss many of the facets that made Doug so special and integral to the magic of Billy's recordings. We also are joined by 5 special guests with unique connections to Doug:  Mike DelGuidice - Guitar and vocals in the Billy Joel band and frontman for tribute band Big Shot. Mike also worked with Doug extensively in the early 1990s.Malcolm Gold - Bassist for The Lords of 52nd Street and the Movin' Out touring band. Malcolm also often plays Doug's basses during Lords shows.Sue Stegmeyer & Kevin Ege - Doug's sister and her husband.Andy Gilmartin - A friend of Doug's when Andy was a teenager, Andy spearheaded getting Doug, Liberty DeVitto, Richie Cannata & Russell Javors inducted into the Long Island Music Hall of Fame in 2014. Andy now is the manager for The Lords of 52nd Street.  For context, here are the albums Doug performed on: Turnstiles, The Stranger, 52nd Street, Glass Houses, Songs In The Attic, The Nylon Curtain, An Innocent Man, Greatest Hits Vol. I & II, The Bridge, KOHUEPT, Greatest Hits Vol. III. 

Please listen to Pastor Stephen Perumalla's sermon titled When God Closes The Womb (Pt. III). If you have not listened to parts I & II yet, it is recommended that you do!  

durée : 01:58:37 - Orchestres baroques III, la filière britannique - par : Christian Merlin - Troisième volet de notre tour d’horizon des orchestres baroques : après l’Europe du nord et la France, voici l’apport de la filière britannique, hissée jusqu’à l’excellence par les pionniers Gardiner, Hogwood et Pinnock. - réalisé par : Massimo Bellini

宏观经济【全球股市上演惊心一周未来或持续震荡】随着新冠肺炎疫情在全球扩散，金融市场不安情绪弥漫，本周全球股市经历了惊心动魄的一周，暴跌和熔断频频上演。分析人士认为，各国央行和政府陆续出台应对措施能一定程度上缓解疫情冲击和安抚市场情绪，但在疫情得到遏制前，市场波动或将持续。（新华社） 【石油价格巨震下的资本众生相产业链悲喜交织】作为“大宗商品之王”的原油，可以生产6000余种产品，所有与之相关的行业都在发生着深刻的改变。而当前业内最大的痛苦是，国际油价的巨幅波动，让他们规避风险的能力大幅下降，因为价格波动已经无关于供需。最大的变量转为了，OPEC能否重启谈判、谈判结果如何、能否达成协议，以及海外疫情会如何扩散、会对需求产生多大程度的抑制……这些问题，现在无法解决，更难以预判。（21世纪经济报道） 【疫情期间科技亿万富翁净资产缩水，贝索斯损失81.4亿美元】据外媒报道，根据彭博亿万富翁指数，截至3月13日，全球前20名科技亿万富翁的净资产均大幅缩水。其中亚马逊创始人兼首席执行官贝索斯净资产总额减少81.4亿美元，微软联合创始人比尔·盖茨净资产总额减少69.8亿美元，Facebook首席执行官扎克伯格净资产总额减少58.9亿美元，谷歌联合创始人拉里·佩奇净资产总额减少43.4亿美元。马云损失19.4亿美元，马斯克损失28.5亿美元。 大沉浮【贾跃亭债务小组：贾跃亭重组信托方案已同步考虑乐视网债务】3月14日，贾跃亭债务处理小组称，其与乐视上市体系和国内相关监管部门一直保持着良好的沟通、对话和实际方案的推进，努力解决与乐视网的关联债务。从2017年7月开始，累计解决上市体系（含乐融致新）关联欠款超27亿元。在此次贾跃亭破产重组的债权人信托方案中，已经同步考虑乐视网相关债务问题。（中国证券报） 【海航集团与部分债权银行座谈，就流动性困难和债务化解进行坦诚沟通】海航集团称，3月11日与工商银行、农业银行、中国银行、建设银行、交通银行及浦发银行等六家驻琼银行行长和代表举行座谈会，通报近期工作、各方关切、存在问题及建议。海航集团已深刻认识到，正如各债权银行指出的，当前面临的不仅是债务危机、治理危机，更是信任危机。海航集团执行董事长顾刚表示，集团已开始安排，将健全完善与债权银行及债权人沟通协调机制。 【网贷平台“铜掌柜”股东自首，涉嫌非吸公众存款被立案侦查】据余杭公安3月14日发布的通告显示，网贷平台“铜掌柜”股东杭州铜米互联网金融服务有限公司法人张某于3月13日主动向杭州市公安局余杭分局投案自首。公安机关决定对其涉嫌非法吸收公众存款立案侦查。此外，在网贷天眼论坛中，早在2019年11月就已有多位出借人表示，该平台频频逾期，出现本息无法收回的情况，杭州出借人也曾集体讨要说法未果。（界面） 新战略联合国推荐了一批软件，钉钉榜上有名。【联合国向全球小学生推荐钉钉】3月13日，鉴于全球新冠肺炎的紧张局势，联合国教科文组织紧急呼吁全球39个国家和地区的4.21亿学生远程上课，钉钉等一批软件成为了联合国推荐的在家上课平台。（国是直通车） 【苏宁易购：3月15日起发放5亿元全民消费券】3月14日，苏宁易购发布消息称，将面向全国用户发放总面值500元全民消费券，涵盖家电、手机电脑、服饰鞋帽、珠宝配饰、生活电器、超市等诸多商品及到家业务品类，消费券总价值共计5亿元。 （中证报） 【字节跳动将在海外推出支付平台】字节跳动正在新加坡组建全球支付团队，将在海外推出支付平台。字节跳动的招聘信息显示，该团队将为公司的产品和服务提供跨境支付平台，以支持公司在全球范围内的迅速扩张。 【百度成立百度健康（北京）科技有限公司，注册资本3000万元】数据显示，百度健康（北京）科技有限公司于3月12日成立，注册资本3000万元，由北京百度网讯科技有限公司全资控股，经营范围包括医疗器械I、II类、健康管理、健康咨询、心理咨询、零售药品及销售第三类医疗器械等。 【网易云音乐推出“音街”App，入局免费K歌市场】网易云音乐近日推出一款名为“音街”的产品。这是网易云音乐首次入局免费K歌市场，并推出独立App。企查查信息显示，“音街”的开发者为杭州乐读科技有限公司，疑似实控人为网易公司董事局主席兼首席执行官丁磊。（Tech星球） 大公司【法国拟批准本国5G网络“非核心部分”用华为设备】路透社12日引述匿名人士的话称，尽管美国呼吁西方国家在5G网络建设中排除中国华为的参与，但法国将效仿英国，允许在本国5G网络的“非核心部分”使用部分华为设备，因为这样较不会构成重大安全风险。（环球时报） 【宝马2019总收入首度过千亿欧元】宝马集团公布2019财年财报，称去年全年集团收入首度超过1000亿欧元，与2009年相比销售额实现翻番。去年四季度销售收入达到历史上销售新高，主要是受益于超高端豪华车板块的销售业绩。（新浪财经）三十多年来首次。【苹果2020全球开发者大会将线上举行，关闭中国以外所有零售店】3月14日，苹果公司宣布，因受新冠肺炎疫情影响，该公司将把一年一度的全球开发者大会（WWDC）转移到线上举行。另外，苹果将关闭中国以外所有零售店，时间持续至3月27日。大中华区以外的办公室都将灵活办公，以应对新冠肺炎疫情。 【微软宣布比尔盖茨退出微软董事会：把更多时间投入慈善事业】当地时间3月13日，美国科技巨头微软宣布，该公司创始人、前世界首富比尔·盖茨将离开微软董事会，把更多时间投入到慈善事业。盖茨也将辞去他在“股神”巴菲特旗下的投资公司伯克希尔·哈撒韦董事会的职务。 【亚马逊和eBay全面禁止口罩等新品上架】亚马逊宣布已经在其网站上屏蔽口罩、洗手液等与新冠病毒相关产品的新品上架。上周，eBay公司也宣布全面禁止销售口罩和洗手液，以防止价格欺诈。沃尔玛和其他电子商务公司也在努力遏制第三方卖家哄抬价格。据此前报道，意大利反垄断机构正在调查亚马逊和eBay，因其平台上包括口罩、洗手液在内的防护产品在疫情期间无理涨价。 观海外 【全球富豪如何应对疫情：负压地堡，VIP医疗，天价口罩】近日《纽约时报》披露了富豪为了避免新冠病毒感染，如何不计成本。有人买400多块一只的口罩，有人交5万块的会费咨询VIP医疗机构，有人花数10万乘私人飞机去山谷中的安全屋，还有人建造了储备齐全的负压地堡。 【7国超30名政要感染新冠：新冠病毒为何深入权利中心？】截至14日，至少已有30余名外国政要被确诊新冠肺炎。当地时间13日，美国迈阿密市长新冠病毒检测阳性，4天前其曾与巴西总统出席活动。同日，巴西驻美大使新冠病毒检测呈阳性，意大利卫生部副部长Sileri新冠肺炎检测呈阳性。有专业人士分析，欧美国家政客社交广泛、活动繁多，其次年龄往往偏大更易被感染。（综合） 【美国迪士尼关闭最后一天数千游客冒雨涌入】3月13日，因为新型冠状病毒在美国的爆发，南加州迪士尼乐园宣布将在星期六关闭直到月底，甚至可能更久。当天，数千游客冒雨涌向迪士尼乐园。据悉，前不久，加州州长纽森召开新闻发布会，宣布行政令，禁止任何超过250人的“非必要”聚会。 加油啊！【世卫组织称任何国家都不能自暴自弃】世卫组织发言人亚沙雷维奇强调，任何国家都不能把“无力回天”当借口，自暴自弃。现在不是相互指责的时候，而是救命的时候。他说，不少国家正在经历中国此前经受过的考验，中国、韩国、新加坡等国的方法，他人可以参考。（央视新闻） 【英首席科学顾问：需六成英国人感染换取群体免疫】此前，据英国天空新闻13日消息，英国政府首席科学顾问瓦伦斯表示，将需要大约60%的英国人口感染新冠病毒以获得“群体免疫力”，从而达到保护全体英国人的目的。瓦兰斯将新冠肺炎描述为一种“令人讨厌的疾病”，但他同时表示，大多数人只会经历一种“轻微的”疾病。（澎湃新闻）

  Egy, khm apró hiátus után itt van aktuális, és mellesleg szülinapi adásunk! A sokadik. Na de ki számolja már? Flash mellesleg könyveket is ajánl (Martha Wells: Kritikus rendszerhiba, Martha Wells: Mesterséges Sors), de inkább az álmairól beszél. Ezúttal kivételesen 18 év alattiak által is hallgatható módon. Ettől függetlenül persze nem feltétlenül ajánljuk bááárkinek. :D Morgan álmodás helyett is olvasgatott, ajánlói: Dan Simmons: Olümposz I-II., Octavia E. Butler: Átváltozás, Craig Alanson: Expeditionary Force. Úgy tűnik, hogy találtak egy földön kívülről érkezett fehérjét. A kihagyás alatt felgyűlt sorozatokból és előzetesekből szemezgettünk: Superman - Red Son, Justice League Dark: Apokalips War előzetes, Resident Alien előzetes, Avenue 5, Doctor Who 12. évad, The Magicians, Star Trek: Picard, Dracula, Castlevania 3. évad, The Expanse 4. évad, For All Mankind, Altered Carbon 2. évad. E heti… e havi dokumentumfilm-ajánlónk: The Fog of War. Néhány hónap múlva jelenik meg Brandon Hackett következő könyve, az Eldobható Testek. Kisebb csoda, hogy a Boeing Starliner első útja egyáltalán félig sikeres volt. Utoljára ment fel az ISS-hez a SpaceX Dragon teherűrhajója. Nevet kapott a következő marsjáró. Összeolvadó viharokat fényképezett a Juno, illetve a vártnál több vizet tartalmaz a Jupiter légköre. Elhunyt Freeman Dyson. Itt az egyik viszonylag rövid előadása a sok-sok érdekes közül. Elérhetőségek: Web oldalunk Discrod Spotify ITunes TuneIn RSS Twitter Facebook Ha tetszett a műsor, ezen a linken támogathatsz minket!

Happy Friday Eve! This week we talk about Harry Potter and the Cursed Child Part One (acts I & II).Next week we'll be back with the second part!

主播：健崔人生似一列火车，从慢慢驶离站台伊始，越来越快，狂奔向前不可追，直到你猛然发现自己不复当时少年，转眼已成儿时印象中的大人。你无力改变这一切，这就是人生的教训。今天的节目就从日本70年代传奇民谣歌手加川良的“教訓 I”开始，上了这一课的我们能不能过好只有一次的人生呢?本期歌单： 加川良 - 教訓 Iなぎらけんいち - 教訓II加川良 - 夜汽車に乗って三上寛 - 夢は夜ひらく加川良 - 伝道遠藤賢司 - 君がほしい早川義夫 - シャンソン大友良英 - 教訓 I工作人员：节目管理：阿聊设计：Common Gender欢迎关注订阅我们：CommonGender了解更多节目信息

In this weeks episode, I interview one of my mentors that I have been learning from for the past couple years. We chat about the journey of his life and the evolution of his career.   2:00 - The Evolution Of His Life 3:30 - Health & Fitness, Relationships, Making A Difference, Earning A Living 8:00 - High School 10:00 - Enclothed Cognition  11:00 - "Be It Until You See It" 16:00 - Developing Your Purpose In Life 18:00 - People Are Our Greatest Teachers 20:00 - Abundance > Scarcity 22:00 - Personal Development 29:00 - How Do You Structure Your Day? 32:00 - Finding Your Purpose 34:00 - 3 Types Of Humans 40:00 - The Problem With Society Today  41:00 - What's Your Honor Code? 43:45 - Creating PR's In Your Life 45:00 - Honesty, Generosity, Wisdom 48:00 - The Power Of Human Connection   More about Dr. Jade Teta: Someone once described me as a mix of jock, science nerd, nature boy & philosopher. It makes sense I suppose. I was a personal trainer for 25 years. I still produce video-based workouts that are used by hundreds of thousands all over the world. It's kind of crazy to think about that number. I have been lucky to find a publisher who knows how to produce and market great products. I have a degree in biochemistry and I am a physician. Although, my friends give me a hard time for never referring to myself as "Doctor." I guess I always found it too formal, have grown past the need for accolades and, depending on who you ask, some don't consider me a doctor at all. Given my specialty in natural medicine, I have been called everything from "quack" to "witch doctor." Believe it or not, I take that as a compliment. The choice to go into alternative medicine was conscious and deliberate. My medical specialty is in a subset of medicine called naturopathic medicine. Think of your family doctor, but instead of using drugs and surgery first, while knowing little to nothing about diet and exercise, I use drugs second and I am an expert in nutrition, exercise and supplements. My specialty is "integrative endocrinology." It's the study of hormones & metabolism. The integrative part just means that I integrate both conventional and alternative methods. Most of my career has been helping the most difficult metabolic cases lose weight. I have a license in California & Washington State and can prescribe all drugs except schedule I & II. I am not opposed to pharmaceuticals and do use them, I just prefer to lean on lifestyle change and natural approaches first. I only prescribe drugs if necessary. There is a time and a place for both. I am also a psychology geek & student of philosophy (my favorites are stoicism & taoism). I started calling myself the "meathead philosopher" after being told repeatedly, "wow, you are really deep, I love your writings, but you also look like you could kick my ass?" hahaha!! I guess it's the bald head and linebacker build? What else can i tell you? I have more life coaching certifications than I can count, I did extra shifts in couples counseling in school (I am fascinated by romance and read research on the topic regularly). I also went through an affair and a divorce. I betrayed (my wife) and was betrayed (by the person I fell in love with). It was the best and worst experience of my life. Have you ever had an experience where you were so hurt, disappointed and embarrassed by your behavior that you hit rock bottom and became a new person as a result? Yeah, that's what happened to me. This is why I write, blog and podcast so much on relationships and romance. I feel I have learned and earned this expertise. I have both the intellectual knowledge and first-hand experience of loss from both sides. I am a voracious reader of anything self development. My two favorite things are working out and reading. Some people like beers and ballgames. Those are great, but I prefer books and barbells. Finally, I am an author. In my field of medicine we have a principle called Docere. It means "doctor as teacher." That's what I spend most of my time doing now; teaching through writing. I write books, and create online educational products on metabolism, fitness & personal development. I teach in three distinct areas, "mind, muscle and metabolism." Hope that helps you understand a little about me? I would love to know more about you as well. How can I help you? Below you will find a link to get on my email list. I would love if you joined my community. The first email I send will ask you how I can help. Take a look around the site as well. You will learn more, and we will have a chance to get to know each other better. Thanks for being here. I genuinely appreciate your interest and support. To Your Next Level -- Jade   FREE 100+ page eBook: Click HERE Website: www.iCoachNutrition.com Instagram: @icoachnutrition Facebook: iCoach Nutrition YouTube: Justin Murphy, BS Nutrition, CPT Twitter: @JustinNutrition LinkedIn: Justin Murphy Email: justin@icoachnutrition.com

This is the first part in a three part series on happiness. Buckle up! We take you into the writings of Aquinas and show how his advice can help you today. Please consider supporting me on Patreon, here. Some of Aquinas' text: Article 1. Whether happiness is something uncreated? Objection 1. It would seem that happiness is something uncreated. For Boethius says (De Consol. iii): "We must needs confess that God is happiness itself." Objection 2. Further, happiness is the supreme good. But it belongs to God to be the supreme good. Since, then, there are not several supreme goods, it seems that happiness is the same as God. Objection 3. Further, happiness is the last end, to which man's will tends naturally. But man's will should tend to nothing else as an end, but to God, Who alone is to be enjoyed, as Augustine says (De Doctr. Christ. i, 5,22). Therefore happiness is the same as God. On the contrary, Nothing made is uncreated. But man's happiness is something made; because according to Augustine (De Doctr. Christ. i, 3): "Those things are to be enjoyed which make us happy." Therefore happiness is not something uncreated. I answer that, As stated above (I-II:1:8; I-II:2:7), our end is twofold. First, there is the thing itself which we desire to attain: thus for the miser, the end is money. Secondly there is the attainment or possession, the use or enjoyment of the thing desired; thus we may say that the end of the miser is the possession of money; and the end of the intemperate man is to enjoy something pleasurable. In the first sense, then, man's last end is the uncreated good, namely, God, Who alone by His infinite goodness can perfectly satisfy man's will. But in the second way, man's last end is something created, existing in him, and this is nothing else than the attainment or enjoyment of the last end. Now the last end is called happiness. If, therefore, we consider man's happiness in its cause or object, then it is something uncreated; but if we consider it as to the very essence of happiness, then it is something created. Reply to Objection 1. God is happiness by His Essence: for He is happy not by acquisition or participation of something else, but by His Essence. On the other hand, men are happy, as Boethius says (De Consol. iii), by participation; just as they are called "gods," by participation. And this participation of happiness, in respect of which man is said to be happy, is something created. Reply to Objection 2. Happiness is called man's supreme good, because it is the attainment or enjoyment of the supreme good. Reply to Objection 3. Happiness is said to be the last end, in the same way as the attainment of the end is called the end.

"Never alone" by Kathy Courtney #32Tagline: "We all more powerful and stronger than we believe and capable of healing from so much more than we think"Sexual abuse, failed businesses, seeing ghosts and so much more has been a part of this amazing women's life. Yet above all these words all I found and saw was true strength. I see a lady who has overcome so much, but shows us all that we are so much, that we are all so strong and capable.We often get into comparisons in life about who struggles the most, but when you hear someone who has been a victim of childhood sexual abuse, only to then still not have an easy ride throughout life but remain radiant, positive and wish a mission to serve others, you can only sit back and smile in admiration.I am so grateful for Kathy sharing her story, showing her vulnerabilities, showcasing her courage and also letting us into her world. Intuitive energy healing is now something she helps so many other people with, as it was the key driver behind helping her overcome her childhood memories. A lady who is on the journey to finding her voice and gaining confidence in spreading her message and one I feel will definitely leave her mark in such a great way.Some key discussion points:Sexual abuse is not your faultUnderstanding supernatural giftsOvercoming business failureRealising your true purpose and passionUnderstanding how strong we truly areThanks for listeningFree Audible book sign up:https://www.amazon.co.uk/Audible-Membership/dp/B00OPA2XFG?actionCode=AMN30DFT1Bk06604291990WX&tag=are86-21Best book on Mindset by Carol Dweck: Mindset https://amzn.to/2QajMvZSupport the podcast: https://www.patreon.com/findyourvoiceLinks to me:Website: https://www.arendeu.comInstagram: https://www.instagram.com/aren.deu/Twitter: https://twitter.com/arendeuFacebook: https://www.facebook.com/aren.singhLinkedIn: https://www.linkedin.com/in/aren-deu-65443a4b/Podcast: https://www.findyourvoicepodcast.com YouTube: http://tiny.cc/51lx6yLinks to Kathy:Instagram: https://instagram.com/kathycourtney7?igshid=1l85l6voewk99Website: https://www.kathycourtney.net Pippa transcript:welcome to an episode of find your voice a movement led by yours truly Aren Deu a guy who was overcome crippling anxiety adversity and difficulty like so many of you in life whose main goal now is to help you combat your excuses take control of your life write your own story and most importantly find your voice so now without further ado I welcome the host of the show himself Mr Aren Deu what's going on people thank you for tuning into another episode a fine your voice my name is Aren and as always I am the host of the show so I'm delighted to have to bring to you today Kathy and Kathy story is one that told me so much in such a short space of time in fact I wish I met her a yeah because what Kathy told me and I'm sure as you listen to this episode it's going to teach you to is that we have so much stronger than we give ourselves credit for I mean how many times have you been to something I think it is going to break you to find that said she made you or if it has a major in that circumstance is definitely made you more resilient more stronger so it's kind of what I want you guys to walk away after this episode is to try and maybe step outside your comfort zone and embrace that fear and take on that little bit of pain maybe for some future gain because I promise you when you head Kathy you see that she's such a more beautiful place right now I have suffered all this incredible amount of adversity from the sexual abuse to losing business is so much more you're going to realize that the human will it's strong it's so much stronger than we give ourselves credit for so I am delighted to have hi there on the show I am extremely grateful that she opened up with have under bill ease and she opened up with this story which is something that I think of the city's more exposure in the road it's something that I wish one day be quit completely see the end of but sadly if we don't what I do want people to do is know that there is a light at the end of the tunnel so without further ado people thank you once again for treating it and I hope you enjoy this episode let's get over to it I want to welcome to the show Cathy thank you for taking time out of your day to come on and share your story how you doing today I'm doing amazing thank you for having exciting I'm happy to be here bless you thank ya I'm extremely happy to have you on the show as well so I was always just a leading to a yeah there's so many elements of your story that that I could relate to but there were also some stuff in terms of the emotional trauma that you experience as a child there's a lot of grief there there's a lot of stuff that we just spoke about very briefly prior to star in this episode that you realized five my life wasn't as normal as you have so it wasn't yeah so I think it be a great place if record if you could stop by maybe give the listeners a little bit more about yourself if you could kind of open up and tell us as much as you feel comfortable with your story okay yeah perfect and so I am the oldest of four children and that those parents were in the home and my dad worked to my mom was a stay at home mom and an eight a one to start with my dad because I see the ad and learned a lot from him my dad %HESITATION contracted polio when he was a very young baby so he was handicap his entire lice on it so I really felt that my first lessons in %HESITATION being compassionate and really being resilient and strong came from hen and watch seen how he dealt with %HESITATION adversity and his life because %HESITATION you know having a parent that wasn't able to walk slowly and eventually in a wheelchair and you know he made sure that we did all the normal things that kids do you you know took us to the beach sand tickets to you you know I'm use net parks and now being a parent myself and those things are hard just for you know up at appearance but but it but now realizing %HESITATION with the disability that he had you know why %HESITATION those things are so difficult and he never complains on he never held back from anything so really I think those were the first lessons that I learned where from him %HESITATION and then there there are two parts to my childhood that really led me ops you kind of the work that I do now which is the reiki healing and also %HESITATION I am a medium so I do you know mediumship readings and I my first memories %HESITATION being a child's where that as being sexually molested at a very early age by my paternal grandfather %HESITATION and dotted use lasted for an extended period of time %HESITATION between six and seven years and %HESITATION also during that time I was starting to experience %HESITATION what what most people would when baby label as supernatural sort of experiences and and by that I mean I would see shadows which now I understand and spirits %HESITATION I would see shadows as animals and people and and the way my mom kinda described it sees that there was always something trying to get my attention so I would be let's have a deep cleaning my room and you know little things that happened things would come off the wall where I would feel a presence in my room and and then there were lots of things that I knew that there was no way of me possibly knowing friend stands I would say %HESITATION the phone was ringing and so once I was calling and my mom would say well the phone's not even ringing and then a minute or two later the phone would ring with the exact same person that that I would say would call and I also had %HESITATION an out of body experience when I was about six I think I was six or seven years old and I might grandparents lives sort of in a in a open kind of country field and they had thrown some sort of poison out for that for the rodents I think and %HESITATION being a little kid just kind of curious %HESITATION I happen to eat the apple is and so fast you know started bleeding internally and you know rest the hospital all that kind of thing and I clearly remember leaving my body and you know I could see the nurses and doctors and all this work being done on my body and so those were memories that I had that I never I didn't understand what was happening at the time and I think a lot of it I did explain to my mom and you know she has seen what kind it is say well let's pray about it or if you would say let's got insert search %HESITATION something like that and then those experiences to students start happening and so she had to move a couple of times because you know she thought well maybe the house was Hines said order and and those those type of things on and so you know that happened throughout my my tile tied on and then when I was about twelve or thirteen my grandmother passed away and %HESITATION I remember she came out of sort of a bathroom stall and you know there there's a mere right in front of me and she appears to me in that mere %HESITATION so those are all things that where we're really %HESITATION you know I wasn't scared of those things you know you're not scared until someone tells you that you need to be scared and exits are wasted it was just a normal thing for me and I thought well does this happen everywhere I just really had no idea yeah at that time %HESITATION and so you know so being you know sexually molested interviews at the time and and that's going on you know it was definitely not what you would say your normal tight why yeah I think I'm gonna have to agree with you that because we were speaking I was trying to say obviously the premise of this show is to let people know that not always alone in in their adversity that they're suffering be you've definitely touched on some stuff that it's almost like a combination of extremes are suppose I've got so many questions I mean is if I may so firstly I just wanna say your dad sounds absolutely incredible and I think he's amazing the fact that I think especially that generation as well with the just the just get on with stuff and and I really love that and I think you almost had like a fish row seat at seeing how to deal with adversity and how to displace life's challenges which probably makes you so strong and empower you know when I can hear yourself now you're in such a great place where is it so easy to probably be in a completely different place haven't been through what you've been through so %HESITATION I think props to yourself and obviously to your father for that then obviously we move on to the more I suppose sensitive subject my way you were sexually molested and yes I'd be doing a disservice as opposed to the lessons and also to myself and if a game please if if this is making you feel comfortable you haven't you don't have to run so but I just want to ask how that affected you when did it stop affecting you in your life or is it still something that you deal with today and it's definitely not something that I deal with today and it's something that it took me a long time to work through and that eight but I have found a place of peace with its %HESITATION you know tearing does a year is I I I guess because of the other situations that were going on in my life I became very good at disassociating myself with the abuse and my emotion around it on and it wasn't until later so I was you know %HESITATION eleven or twelve years old when you know most kids are going through those changes where you know you're you're not a child that you're awesome not a teenager and and so you know I definitely went through a lot of it and just completely hating myself you know south heat and the prior question and stealing %HESITATION so isolated in those feelings and I'm just a lot of different emotions you know but mostly it was the south heat I completely hated myself now I didn't like the way I looked and I didn't like the way I felt and I didn't like my late tonight I didn't like anything about me and so that you know that I can say that that's how it affected me and then and around I think it was around eleven when I was really going to the changes %HESITATION might I started experiencing like a real physical keen in my body it was intense pain I'm I literally like I would say I stopped walking because my body was in so much pain and my mom you know my mom took me to the doctors they couldn't find anything really medically wrong with my body I'm and now looking back I knew and because of the work I do now I know I know that it is that it was that energy of that trauma that was stuck in my body and the energy of not being heard and not being able to speak up for myself that I was experiencing a real physical pain %HESITATION and it ended up that the doc they thought maybe it was index and they thought it was something you know with you know my female I guess organs and I I had a surgery had surgery because they did not know what to do with me they didn't know what is wrong with me on and so now looking back I think that's totally crazy that you know it went that far but at the time and I don't think that I was able to verbalize you know what happens to the extent that it happens %HESITATION I felt that a lot of that was covered at my extended family and I eat I literally didn't know what to do and now I know like I said I just think it was the pain of that trauma that my body was experiencing why am and just on the as you were saying that there was %HESITATION there was a quote that I listen to your car remember exactly where it came from but it says to heal the wound you must feel of wind and really resonated with me so not in the respect that I've been through what you've been to but I had been physically a so it to the point that I was almost left for dead a long time ago it's a story for another day and somewhat of a vote to shed but for me to be able to really have overcome that and went through the process of forgiveness and really trying to go back into that moment running kind of just plastering over and pretend it never happened it was only then my lifestyle to really change so would you say that was highly of the seat I know you're into you you do healing therapy now is off is that how you find your way of really moving on I suppose from the trauma you experienced and then releasing yourself and I no longer hopefully experiencing physical pain yeah eight it was a combination of things on I think after that experience with the surgery and jazz really you know I've always been very into it as %HESITATION and I've always been very in tune with my cells %HESITATION even though sometimes I didn't have the words to express what I was feeling I didn't feel like I have the support on I knew that that my life wasn't always going to be that way you know I knew that even as a young child and %HESITATION you know I would turn on it with read and so it seems like I've always been into like self help and self healing even at a very young age %HESITATION that there were lots of little incidents after that you know I I found myself in that piece of near it first marriage in which I quickly got out of that %HESITATION and then I went on to start a business with my current husband his amazing and supportive and I love him and %HESITATION things are going well with that and then a recession hit %HESITATION unfortunately and so we we pretty much lost it all and see now all the money and all the hard work that we had to put in sweats and so I also had it needs a new baby at the time and then you know go in trying to trying to rebuild from that %HESITATION and then I find out that my dad on has a terminal illness called pulmonary fibrosis and he was given six months to live so you know it's like a one thing happens and then you know now I am I'm caring for my newborn and and then I find out I'm going to have another child and then navigating through caring for my children and for my dad you know and and walking him through the process of his journey into his transition because you know he he only has six months to live at that point %HESITATION and so you know that was a beautiful gift but it was it was a difficult guest as well just just seen him go through that and then %HESITATION you know but I I did make a promise to him because we had we had all this ad tying Ted to talk about all the really important things and on my child's head in his childhood and and just a really understanding of each other and %HESITATION you know he made me promise that after his his transition I would get censored if there be I would seek out help I would seek out since ready healing and because not only was I going to have to heal from my childhood just that the fact hearing from from losing him because he he does quite literally my best friends so I went on to you know I I I need a promise to him and I was gonna sell sell that promise so I did seek out a couple of therapists and it was you know talk therapy and I I really didn't feel %HESITATION that I was making much progress and so someone mentioned %HESITATION EMDR so %HESITATION I don't know the specifics of how it %HESITATION that I did a couple of sessions with that and it was amazing %HESITATION and then one of my best friends who she's been on this journey with me sensor might style tent I'm she sat and at the time I was really into meditation I got into meditation and started really %HESITATION implementing a spiritual practice of my own and so she said Hey I heard about this healing circle it's a meditation circle I think you would really really really enjoy it and so I decided to go and that was my first experience with energy healing I had an energy healing session there and it was such a release I he asked out so much come out of my body I had this experience where I sell to my dad and in the presence of that room %HESITATION I saw him I heard him I was able to talk to him it was the most amazing experience and I left there and thinking what was that you know what is that I have to learn more about this and and so that's how I found my my first my first mentor and with that Brady Ricky healing this incredible yeah I was it was amazing just on that then so you know how you're having these experiences and I know you went on when you had the poisoning you run the in your life and obviously with your dad is that something that you're in control of or is it something that you can maybe manifesto is it just completely random when it happens I mean now it doesn't happen as often %HESITATION but it's something I can control within myself you know I'm not walking around is leaving my body that's good to know no and I'm just on everything else that you see you said that was going to say how inspiring it is because I always find when somebody goes through so much trauma so much adversity but they only see the gift from it and have a completely different perspective like yourself we said you so blessed to have all these gifts yet you've gone through so much stuff almost that you have to sit back and think how does one person cope with so much adversity so you extremely inspiring with that and I wanna ask what's your secret for continually rising each time you're not down with something and I think so I don't know that I had a cigarette I do have a spiritual practice that I uphold too and I am constantly working on mice cells %HESITATION that they think it's just really reflecting on and my dad you know I mean we I do this in in in his honor really I do this for my children I do this for other people at cyber Cup myself so that I can work on others because I want people to know that no matter what you go to in right now %HESITATION there's always a light at the end of the tunnel and and you're gonna make it through that's hard absolutely and I'm I'm extremely glad that you kept your promise to dining you you did seek the help because you're now in a position of the way you can help so many more people which is which is fantastic so good on you and then the MDR defeat sounds interesting to gain I think we spoke about this offline and this is our really kind of for a selfish reason just got fascinated by your story because I've always been interested in the whole heating in the spirituality side I think the only difference to me and you is it Faisal my grandma are in the mirror out will things fun of the war I would absolutely crap myself I would be running out of the house in anything so %HESITATION again you touched on a very good point though because I was gonna ask you the question is you only become scared of things in life when people tell you that you may be sure to society says that and then also if I was a kid I mean thinking about now I lived in my aunties has pretty much all the time I was always around with my cousins and I'm sure there was some men where things happening in the house but it felt home to me where is not %HESITATION I'm a grown man on the left they ease and if I have to go and stay there by myself on the not a problem he turned it down %HESITATION from inside some round so hopefully she's not listening to get offended but isn't it isn't it funny how the how the world works but I just think it is a beautiful gift I have been told in the game correct me if I'm wrong that be your have this ability to soft top into this kind of is it that audio this intrusion not with another high level %HESITATION yes I believe we all have we I have that ability to tune in to to spirit to the divine %HESITATION to our guides week we all have that ability I think sometimes you know we do go through different different things in life where we're not taught that we are able to do that I think that might be a disservice to lots of children you know because children don't question things they they're not afraid of things you know it it was very natural and normal for me and to have those connections %HESITATION and sometimes you know the way you know different people have you know sort of religious beliefs or that that conditioning of the way they've been raised %HESITATION wherever they are in the world and so sometimes you know that'll start kind of diminishing does start a connections because then we think what is Israel is this wrong %HESITATION should I be afraid you know but I think you know even with my own children %HESITATION my son is extremely empathic %HESITATION my daughter she also is very connected as a matter of fact %HESITATION after my father transition and ours was about three or four she started connecting with him she would see him and speak to him and %HESITATION she would tell me what he would say and then all those those memories and my childhood I'm I'm having this connection started coming back because I thought this is exactly what I thought when I was her needs %HESITATION yes so yeah all children we all do now we I have we all have the ability to connect with our loved ones %HESITATION have transitions and yeah I definitely believe that I think you hit the nail on the head that children are predicting that the fact that they remain curious and the Phyllis so I kind of wish Buell kept up a summer long life through Janie whether it's his old teachers or family we kind of really you stop and we start to be become afraid of things that maybe we shouldn't necessarily be afraid of them stop becoming curious because you're kind of pigeon holed ourselves into little pocket so surprised and it's a shame but I'm just I'm not then I just wanna ask something I'm playing devil's advocate here some people will probably think that the stuff that you and I believe in is a little bit ferry Talysh or something that doesn't exist for example so if we accept that there are people with their own beliefs which is absolutely fine but they've experienced the symbol of control missed yourself on the sexual abuse for example what would you recommend for somebody dealing with that pain at all they're all tentative is other than the whole spiritual healing is there anything that you could recommend perhaps again that the might not be in on some just asking as you can now looking back you know and there there's so many different healing modalities and there's so many different ways to go about healing you know energy healing as is only one of those things see now and %HESITATION I would say just find something that resonates with you whether that rare some people will feel very connected to to going to church and to praying %HESITATION meditation meditation was a huge %HESITATION practice for me that helped me on EMDR is is is something that you can go to a therapist for %HESITATION you know had no therapy there's so many different avenues %HESITATION and with the energy healing our rate your whatever it is that you choose to do %HESITATION that can really be a compliment to to lots of other things that you know it doesn't have to be one right of one modality you can pick and choose and and kind of find something that works for you but you know if I can say one thing on that %HESITATION I would say you know to stress the importance of of whatever type of healing that you signs whatever resonates with you that how important that is because and you know just I'm working on my cells and working on others %HESITATION I calm now now looking back I have learned that I come from a long line sort of abuse on both sides of the family and sexual abuse and and physical abuse and incest at an ancestral line but you know when you decide to step forward and and you'll those those things in in your %HESITATION in your life you're not only healing yourselves but you're healing your ancestral line and you're also healing for your children you know so that they don't have to carry that forward in their DNA and they don't have to go through the same things he went through so that's to me that's amazing and every time I see that and someone and I'm just so happy and excited for them because it it'll stop with you you know once you seek out that healing and that's an amazing thing to think I yeah absolutely because because it becomes a purpose be getting yourself which then obscene spies you right absolutely okay so touching on the final thing that I want to ask you which was about your business that you and your husband hadn't invested so much time and energy into which I sadly file during the recession what's the situation now what are you doing right this moment I will now looking back you know at the time you don't you don't kind of makes sense of things are happening %HESITATION but now looking back I don't think it was my journey it wasn't my past and so it didn't work out and I would have been tied to something that I did not live at the time I thought that this was money this is my passion I I was a hairdresser and so I did here and make up and %HESITATION %HESITATION I did a lot of weddings and so I opened up a bridal shop because that's a lot to weddings I'd love to be around happy time in people's lives and %HESITATION but now looking back on that was never really might have you know that was never really my journey %HESITATION in so how to have the business I wouldn't be doing what what I'm doing now I would have been able to spend that lasts six months with my dad definitely not because you know business of course as you know takes up so much time and energy and money and worry and stress so after after you know pretty much losing at all I mean we had it well that was that was a difficult time but on so my husband continue to work what you know he never he never quit his job %HESITATION and so I went on to just be leave work on healing my cells and I like I said I took training and what I do now which is freaky healing and and shortly after you know I really went into it because I was the one that needed the healing I never thought that I was going to use this to help other people right I definitely didn't think this was going to be what you call a business or anything of that sort %HESITATION diet I started really experiencing all those things I had experiencing experienced as a child so a lot of the mediums abilities came back and I noticed that every time I was you know practicing or working on someone %HESITATION I was connecting to someone on the other side %HESITATION and so that that led me and so what I do now mailing this incredible and I just want to pick up on a point that you said that you never went into it for yourself initially and you can never realized on the CD the wider impact I suppose you could have done and the funny thing is is a little bit about myself so ins I II has literally been my shadow for the majority of my life and when I started this podcast find your voice and when I first I do need about public speaking in just just trying to get out there and I joined Toastmasters and stuff a lot of it was just solely for myself it was to grow and right it was the kind of overcome the fears and I was going through this growth mindset thing thinking I'm not going to accept that in this very short amount of time I'm just going to be much like it for the rest of my life so I kind of threw myself out there and face my face but on the back end of that I realize the inspiration that is given to the people's all all will get her very run a message once in awhile from somebody saying every time you post even though you might for me for like a very mundane post because I pretty much do the same stuff every day it's saying you inspire me every day how you always just the high side your compass own and then I realize even in this podcast the power that we have in terms of one sharing I've learned abilities but then to try to overcome so that not really resonated with me because now I almost feel like the podcast especially is it's become a passion I'm just developed such an interest in a one of kind of mass three I want to become the best in the work I really want to spread messages like yourself and all them other fantastic guest out there in the votes of you'll don't shy away from our affairs and we just did she lived that charge %HESITATION being how children are like we spoke about earlier and just buffet listing curious about life yes I love that that's amazing I think you're amazing thank you blabla see that's your amazing and I just wanna ask actually just fun now knowing where you are you've come to find I believe your passion I yeah what's your daily routine like that so I pretty much do the same thing every day I get up pretty early I start my day by meditating so that something I don't ever deviate from I meditate %HESITATION and then I will journal a journal every morning and S. I'm reading a book which I tend to always read I'll read a couple of pizzas and then %HESITATION now this is a kind of kind of changes sometimes I go from going to the gym and sometimes and right now my habit is just I really like being outdoors so I start my day by either a walk or jog which really turns into kind of a shop full and I been listening to podcasts every single morning on my box so I need to do that and then I'll come back and work out and then I'm ready for my day %HESITATION but that's every single morning every single morning I did not this brilliant and within that you can see straight away there's a lot of self care and a lot of self love that goes into that so you kind of want any G. enormous revitalizing yourself before you kind of talk with the day which is right which is fantastic yeah and %HESITATION have you got any other hobbies other than what you do outside have you wreck and so I mean I love to read I have to spend time with family and friends I home school my children so that it pretty much takes up a lot and then you know of course in my clients and %HESITATION I don't know that their hobbies but there are things that I enjoyed doing and just being with my children really right now and and spending time with my husband excellent and I just wanna ask another question if I may Sir I have so many questions because a fascinating how you trying to spread your message in your because I believe you have a incredible story I believe you you can always help people in so many ways have you got like a you tube channel is not something in the part time or are you thinking about increasing Instagram I am thinking about open yeah so my Instagram spin %HESITATION I ate so this is kind of been a journey for me and it's it's it's been private for a very long time because %HESITATION met so where where I live and I think in general and there's been a lot of sort of back last when I started to take open up into more mediumship readings and %HESITATION to really do that some people are very strongly against not on so that was a little concerned when the fact that I do have children I didn't want that to affect them in any way %HESITATION but we've had we've had lots of moments are we talked about this and you know there's always going to be somebody that doesn't believe in what you do and doesn't like you so mostly right now all my workers just been word of mouth on there's a local magazine I've been fortunate enough here to write for eight and a couple interviews for that magazine %HESITATION and and I have my website and so that's basically but really it's just being out %HESITATION in my area a lot of clients sending more clients and say that it's been amazing but yeah thank goodness yeah I am going to start working on some more things %HESITATION I tend to procrastinate a little bit in that area out which I am I am working on that my husband gets a little irritated with me but yes I am opening up more and more slowly absolutely I gain is this approach this isn't it I mean our member initially so I come from a very academic background again I was always a shy kid yeah I would be doing the most random stuff in terms of our discredit you tube channel or I would just stop doing videos and it was almost read because people would say are you really that sorry but what they didn't see was that it would take me five hours to release a two minute you to video because on a on a three hundred the tents for and then the beautiful thing the allied with the channel was not I could manipulate it so much and cried with the is an all as an almost made myself if it and then somewhere along magenta realize actually that's not really the perception I want to be given a in fact let's just where my floors and we must because that you say guys this is kinda how I am I'm still working on it so I think definitely get you some case off I don't think instagrams a burning platform and I've spoken to a couple of them ladies you about you coming apart castle just offline actually and they have Instagram TV where they'll just do like minute videos or a couple of minutes video the day or maybe a week again oversee depends in you punch Cup but it really does give great value and slowly you can start to see the people who are engaged with the menu almost crate a community because as with myself I could say one messages somebody next %HESITATION could say the same message but the audience might resonate with them more than me or vice versa that makes sense I think yeah that makes perfect sense yeah and I think you're definitely get your orders and I just as you said something earlier I just want it was it was a call from Eric Thomas is a motivational speaker he says there's a group of people that need you more than you need to listen to the negative comments I love that I loved as a because in your back your mind you're worried about what these negative comments going to say but we really have to get people like yourself out there because like he says is a group of people that you need you I need this message so a ride takes on one of the truly I mean a tree down on a quite a hobby and I have a certain number of calls today and always just look at and it just kind of keeps me focused on my journey because if I listen to naysayers of people saying why are you doing this or don't you find it where that you'll try to put yourself on the Indians and almost kind of change and feel like it's my G. to kind of shape people's stories like I get to sit with you not for now and I learned so much from your adversity from you we stem from the way that you say I think that is an injustice if I don't share that with the road thank you for sharing that with me I love that yes yeah and that's something I've I've been I've been trying to work for a while now and again I think it kind of goes back to raise a child and you know I I I I receive a lot of negative comments and even now as an adult now %HESITATION I have tried to reach out to different areas %HESITATION and people have not been so nice that there which I totally understand and I'm fine with it but %HESITATION I I'm definitely working on that right you know we're out kind of a work in progress exactly exactly nobody has it figured out rule kind of just figuring it out as we go along yes it is about just finding your network because well I realize was again just on a quick tangent when I started my you tube channel my initial frustration was because my friends and family wasn't supporting it and then what I'm what I'm very quickly realize was that was not my audience that I needed to say yes that is such an amazing point yeah it is the only kit like eighteen months down the line so I know this resentment and all this kind of frustration and the prime into really realized hold and iron that's not who you need to be said doing so then I changed my focus and even I with this podcast my news feeds and the people in truck with a completely different to myself say twelve months ago because I need to be in a community where there are people who need healing there are people who just need the inspirational motivational somebody's contract vested not card trying to connect the dots if that makes sense and just make their life a little bit easier so yeah it's interesting I'm looking forward to your journey and hopefully you see a lot more fun to untested the next question as you probably know is going to be about investing on %HESITATION we've kind of touched on that very briefly at the beginning so by all means choose any type of investor that you've been through a lot that can be business for lady can be passed on or whatever okay but the main thing I want to know from this is just the lessons that you learned from it and what you can then take from that situation and move forward with a loud and I I think you know I've learned a lot through through the things I've gone through and I I think the main thing is that humans in general are so much stronger than I think we're even led to believe that we can take our stories on the trauma and the good points and all those things and just really use that to help other people and to let them know that they won't get through it as well %HESITATION but really I think it's just wow people are so strong and we don't even realize that what we're going through three those situations but how amazing we are your amazing and I think when people listen to this story people are gonna realize why we're even stronger so it's one thing thinking was strong and let me go straight face TV almost come out the other side and it's like that saying what doesn't kill you makes you stronger but when you have somebody else and this is why I love stories like yourself he's been through so much more and more and then so come out the other side and just has this radiant energy of just love and no resentment or any sort of a %HESITATION feeling it is very funny just shows your wives even more street that we can tap into thank yell and in this moment then why not what's your biggest fear %HESITATION something happening to my children and something happening to them and so I I do tend to be a little over protective with my children which I'm also working on that is that the home schooling as well no not so much no not so much the home schooling it's just I'm you know I'm very aware and people that are around my children at all times and %HESITATION yeah I am I am I am worried about something happening to my children I don't want them to have to go through the same thing that I that I experienced on so I would say that would be my biggest fear and that's very understandable thank you and next before we go into the from pie the show where I'm gonna put you through your paces I just want to ask for help %HESITATION in this moment is you'll inspiration you why for what you do what you do my children my children especially I wanted to see my my daughter because I want them to know that they can constantly reinvent themselves they they don't have to know all the answers you know by the time they're eighteen or nineteen at %HESITATION you know I want them to see that now I think all these different things I've done all these different things and I am still working on it so just do what makes you happy %HESITATION you know speak your truth I want them to know that so that's why I'm constantly and I am working on that because I want my daughter to you and my son of course but to speak your truth %HESITATION said they they are my why they are my inspiration for sure love this it should be for message and I think in a society where we're almost hypnotized with this poll of trying to fit in in trying to walk a set way trying to vice saying things and I'm just conform to I suppose what to site once she's very difficult to be ourselves right it would be beautiful to see more people really just trying to really embrace who who they are Hey at each stage of your life you know you don't you don't have to have all the answers yeah absolutely I'm still trying to figure one answer right that's correct but yeah we'll get that and so we are actually not what the form part of the show and this is kind of the show the pa the show sorry where I would just ask you the most random questions for sixty to ninety seconds we're gonna start in three two one if you could abolish one thing in the road what would it be %HESITATION crimes against children your favorite hobby reading your biggest role model my cat what would you like to be remembered for my your biggest goal this year to get out in a %HESITATION some heartfelt snacks and new people and and just really connect with others your west mistake my first marriage no if you could relive one day again what they would it be any day with my dad the ability to fly or be visible fly the number one thing that annoys you liars money or fame many your proudest moment giving birth to my children your favorite food would you rather speak more languages we'll be able to speak to animals I feel like I can speak to animals so I mean if you go with all languages if you had an extra hour day how would you spend any time with my children sixty two your favorite TV show ever I merely lab and I still really laugh the old classics like my legs on show I love those because they would you rather know how you would die or when you were done house and finally what is one question that you wish I had asked you covered at all and does this is amazing well bless you so that was nice and the next question when asked just before we move on to the final question is about reflection and the call I'm a firm believer that hindsight is a wonderful thing because obviously upon reflection we can always think of ways to get to places quicker easy how would less heartache what I want to know is if you could go about knowing everything that you know not too young and healthy maybe during your early years between the ages of eight to ten %HESITATION whatever agent was and you can just whisper something in the air knowing exactly what you know now what would it be %HESITATION I think in regards to the abuse that I suffered I would say it's not your fault this isn't your fault none of this is your fault %HESITATION that would be huge and did you believe it was your full at that at that particular time I thought I did something wrong definitely I thought I thought it was something I did wrong and I and I believe that for a long time you know so yeah I would definitely say that thanks for sharing if I may just ask on that was it was it difficult for you to come out and let your family know about it I mean how did the how did that let's change the fuck on %HESITATION so that was a totally different you know that's a whole story in itself but I'm like I mentioned my best friend who invited me to the meditation circle we were friends in middle school so I think by this time I'm eleven or twelve years old I don't know but I was just going to such a difficult time and like I said I was in so much physical pain %HESITATION that I opened up to her and I mean she was you know another child basically and and so she went to the school counselor and so the school counselor called me in and then called me parents and and so that's how it came now but by this time it was already you know seven years and but there was a lot of threats being named by this person so I was afraid yeah I was trying to ruin the family I was afraid I was going to get hurt to think he was going to hurt my appearance on I was afraid of not being believes %HESITATION and then at some point you know do you it's so common that in a way you accept it which is a strange concept but it just becomes your life and you don't know any difference at that point so excited even out I don't think that that you know at the earlier stages I didn't know was an option to to to speak out about and say Hey this is happening and this is %HESITATION county what should we do right I I literally had no idea and because it was so it was so common and it happened so many times that it just became my life who's thank you for sharing the thing yeah and just finally then so this is actually the last question I always love trust my guess and it's about let okay so if in a hundred fifty years time signs vows to save his soul and all that exists is a book and this book has everything that you've done in your life for the weight and wonderful things firstly what with the title of the book be and second what the Blair but the back tell us about coffee I think I would want the titled Sabine never alone and and I think I'd want it to really express that you know I was a compassionate he's sick kinds of person %HESITATION but I think I would want it soon you need expressed the fact is that I would want others to know that we all have this in our guidance and this and make healing power with an S. on that even you know in those darkest moments when we feel alone that we are able to tap into that in tune into that and that we are definitely more powerful than we hi to believe %HESITATION but I'd really want people to know that %HESITATION that they have this amazing ability inside them they will be much more courageous if we knew how strong we could truly be so that's right absolutely and Kathy suddenly dies obviously the end of that the questions but I want to give this I want to give you an opportunity and we get to guess an opportunity to obviously connect is also what's the best place that the list is can reach out to you and so I have a website it's Kathy Courtney dot net and I am on Instagram Kathy Courtney seven %HESITATION but definitely there my website if someone had any questions or you've definitely reach me on their phone testing and also to the website that I mentioned anyway I actually read your story and he and he was fascinated I'm so glad that I did read that story I did reach out pain because here I am myself too I mean this is been absolute pleasure energy as everyone listening to follow Kathy again if you go on even now with Instagram page we are following you %HESITATION you'll messages even in your captions and stuff is always in a message there but our I'm looking forward to you really coming out of your shower metes Stein T. share your life because this this conversation has been really enlightening for me I really do appreciate you sharing your vulnerabilities as well also thank you for taking time out of your day today and I want to also thank the leases well thank you for listening thank you so much I really appreciate you and remember this podcast is absolutely free so all we ask in return is for you to share this with a friend and drop us a five star review over on iTunes have an awesome day See acast.com/privacy for privacy and opt-out information.

Thanks for listening! Please support me on Patreon (Thank you!) here. Check out that photo of me and Br. Joseph here. Here's the text I read from the Summa II-II, Q.2 (articles 1,2, and 3). I answer that, "To think" can be taken in three ways. First, in a general way for any kind of actual consideration of the intellect, as Augustine observes (De Trin. xiv, 7): "By understanding I mean now the faculty whereby we understand when thinking." Secondly, "to think" is more strictly taken for that consideration of the intellect, which is accompanied by some kind of inquiry, and which precedes the intellect's arrival at the stage of perfection that comes with the certitude of sight. On this sense Augustine says (De Trin. xv, 16) that "the Son of God is not called the Thought, but the Word of God. When our thought realizes what we know and takes form therefrom, it becomes our word. Hence the Word of God must be understood without any thinking on the part of God, for there is nothing there that can take form, or be unformed." In this way thought is, properly speaking, the movement of the mind while yet deliberating, and not yet perfected by the clear sight of truth. Since, however, such a movement of the mind may be one of deliberation either about universal notions, which belongs to the intellectual faculty, or about particular matters, which belongs to the sensitive part, hence it is that "to think" is taken secondly for an act of the deliberating intellect, and thirdly for an act of the cogitative power. Accordingly, if "to think" be understood broadly according to the first sense, then "to think with assent," does not express completely what is meant by "to believe": since, in this way, a man thinks with assent even when he considers what he knows by science [Science is certain knowledge of a demonstrated conclusion through its demonstration.], or understands. If, on the other hand, "to think" be understood in the second way, then this expresses completely the nature of the act of believing. For among the acts belonging to the intellect, some have a firm assent without any such kind of thinking, as when a man considers the things that he knows by science, or understands, for this consideration is already formed. But some acts of the intellect have unformed thought devoid of a firm assent, whether they incline to neither side, as in one who "doubts"; or incline to one side rather than the other, but on account of some slight motive, as in one who "suspects"; or incline to one side yet with fear of the other, as in one who "opines." But this act "to believe," cleaves firmly to one side, in which respect belief has something in common with science and understanding; yet its knowledge does not attain the perfection of clear sight, wherein it agrees with doubt, suspicion and opinion. Hence it is proper to the believer to think with assent: so that the act of believing is distinguished from all the other acts of the intellect, which are about the true or the false. (Article 1)   I answer that, The act of any power or habit depends on the relation of that power or habit to its object. Now the object of faith can be considered in three ways. For, since "to believe" is an act of the intellect, in so far as the will moves it to assent, as stated above (Article 1, Reply to Objection 3), the object of faith can be considered either on the part of the intellect, or on the part of the will that moves the intellect. If it be considered on the part of the intellect, then two things can be observed in the object of faith, as stated above (II-II:1:1). One of these is the material object of faith, and in this way an act of faith is "to believe in a God"; because, as stated above (II-II:1:1) nothing is proposed to our belief, except in as much as it is referred to God. The other is the formal aspect of the object, for it is the medium on account of which we assent to such and such a point of faith; and thus an act of faith is "to believe God," since, as stated above (II-II:1:1) the formal object of faith is the First Truth, to Which man gives his adhesion, so as to assent to Its sake to whatever he believes. Thirdly, if the object of faith be considered in so far as the intellect is moved by the will, an act of faith is "to believe in God." For the First Truth is referred to the will, through having the aspect of an end.  (Article 2) I answer that, Wherever one nature is subordinate to another, we find that two things concur towards the perfection of the lower nature, one of which is in respect of that nature's proper movement, while the other is in respect of the movement of the higher nature. Thus water by its proper movement moves towards the centre (of the earth), while according to the movement of the moon, it moves round the centre by ebb and flow. On like manner the planets have their proper movements from west to east, while in accordance with the movement of the first heaven, they have a movement from east to west. Now the created rational nature alone is immediately subordinate to God, since other creatures do not attain to the universal, but only to something particular, while they partake of the Divine goodness either in "being" only, as inanimate things, or also in "living," and in "knowing singulars," as plants and animals; whereas the rational nature, in as much as it apprehends the universal notion of good and being, is immediately related to the universal principle of being. Consequently the perfection of the rational creature consists not only in what belongs to it in respect of its nature, but also in that which it acquires through a supernatural participation of Divine goodness. Hence it was said above (I-II:3:8) that man's ultimate happiness consists in a supernatural vision of God: to which vision man cannot attain unless he be taught by God, according to John 6:45: "Every one that hath heard of the Father and hath learned cometh to Me." Now man acquires a share of this learning, not indeed all at once, but by little and little, according to the mode of his nature: and every one who learns thus must needs believe, in order that he may acquire science in a perfect degree; thus also the Philosopher remarks (De Soph. Elench. i, 2) that "it behooves a learner to believe." Hence in order that a man arrive at the perfect vision of heavenly happiness, he must first of all believe God, as a disciple believes the master who is teaching him. (Article 3)

In today's episode we'll take a look at the following questions: Is it possible to hate God? Is hatred of God the greatest of sins? Is hatred of one's neighbor always a sin? Is hated a deadly sin? If not, from what deadly sin does hatred arise? We'll also be reading a lot from Dostoevsky's Notes From Underground. Here's the edition I have and recommend. --- Please support my work --> https://pintswithaquinas.com/donate/ --- Here's the main article we look at from Aquinas in today's episode: Whether it is possible for anyone to hate God? Objection 1. It would seem that no man can hate God. For Dionysius says (Div. Nom. iv) that "the first good and beautiful is an object of love and dilection to all." But God is goodness and beauty itself. Therefore He is hated by none. Objection 2. Further, in the Apocryphal books of 3 Esdras 4:36,[39] it is written that "all things call upon truth . . . and (all men) do well like of her works." Now God is the very truth according to John 14:6. Therefore all love God, and none can hate Him. Objection 3. Further, hatred is a kind of aversion. But according to Dionysius (Div. Nom. i) God draws all things to Himself. Therefore none can hate Him. On the contrary, It is written (Psalm 73:23): "The pride of them that hate Thee ascendeth continually," and (John 15:24): "But now they have both seen and hated both Me and My Father." I answer that, As shown above (I-II:29:1), hatred is a movement of the appetitive power, which power is not set in motion save by something apprehended. Now God can be apprehended by man in two ways; first, in Himself, as when He is seen in His Essence; secondly, in His effects, when, to wit, "the invisible things" of God . . . "are clearly seen, being understood by the things that are made" (Romans 1:20). Now God in His Essence is goodness itself, which no man can hate—for it is natural to good to be loved. Hence it is impossible for one who sees God in His Essence, to hate Him. Moreover some of His effects are such that they can nowise be contrary to the human will, since "to be, to live, to understand," which are effects of God, are desirable and lovable to all. Wherefore again God cannot be an object of hatred if we consider Him as the Author of such like effects. Some of God's effects, however, are contrary to an inordinate will, such as the infliction of punishment, and the prohibition of sin by the Divine Law. Such like effects are repugnant to a will debased by sin, and as regards the consideration of them, God may be an object of hatred to some, in so far as they look upon Him as forbidding sin, and inflicting punishment. Reply to Objection 1. This argument is true of those who see God's Essence, which is the very essence of goodness. Reply to Objection 2. This argument is true in so far as God is apprehended as the cause of such effects as are naturally beloved of all, among which are the works of Truth who reveals herself to men. Reply to Objection 3. God draws all things to Himself, in so far as He is the source of being, since all things, in as much as they are, tend to be like God, Who is Being itself. - ST II-II, Q. 34, A. 1  

Today I sit down with philosopher, Dr. Frey to discuss life. A much more difficult issue than you might think. Here's two of the main texts' from Aquinas that Dr. Frey and I reference ... I bet if you read these excerpts after listening to the show they'll make a lot more sense.  Please support my work (Thank you!) at patreon.com/mattfrad --- Whether life is properly attributed to God? I answer that, Life is in the highest degree properly in God. In proof of which it must be considered that since a thing is said to live in so far as it operates of itself and not as moved by another, the more perfectly this power is found in anything, the more perfect is the life of that thing. In things that move and are moved, a threefold order is found. In the first place, the end moves the agent: and the principal agent is that which acts through its form, and sometimes it does so through some instrument that acts by virtue not of its own form, but of the principal agent, and does no more than execute the action. Accordingly there are things that move themselves, not in respect of any form or end naturally inherent in them, but only in respect of the executing of the movement; the form by which they act, and the end of the action being alike determined for them by their nature. Of this kind are plants, which move themselves according to their inherent nature, with regard only to executing the movements of growth and decay. Other things have self-movement in a higher degree, that is, not only with regard to executing the movement, but even as regards to the form, the principle of movement, which form they acquire of themselves. Of this kind are animals, in which the principle of movement is not a naturally implanted form; but one received through sense. Hence the more perfect is their sense, the more perfect is their power of self-movement. Such as have only the sense of touch, as shellfish, move only with the motion of expansion and contraction; and thus their movement hardly exceeds that of plants. Whereas such as have the sensitive power in perfection, so as to recognize not only connection and touch, but also objects apart from themselves, can move themselves to a distance by progressive movement. Yet although animals of the latter kind receive through sense the form that is the principle of their movement, nevertheless they cannot of themselves propose to themselves the end of their operation, or movement; for this has been implanted in them by nature; and by natural instinct they are moved to any action through the form apprehended by sense. Hence such animals as move themselves in respect to an end they themselves propose are superior to these. This can only be done by reason and intellect; whose province it is to know the proportion between the end and the means to that end, and duly coordinate them. Hence a more perfect degree of life is that of intelligible beings; for their power of self-movement is more perfect. This is shown by the fact that in one and the same man the intellectual faculty moves the sensitive powers; and these by their command move the organs of movement. Thus in the arts we see that the art of using a ship, i.e. the art of navigation, rules the art of ship-designing; and this in its turn rules the art that is only concerned with preparing the material for the ship. But although our intellect moves itself to some things, yet others are supplied by nature, as are first principles, which it cannot doubt; and the last end, which it cannot but will. Hence, although with respect to some things it moves itself, yet with regard to other things it must be moved by another. Wherefore that being whose act of understanding is its very nature, and which, in what it naturally possesses, is not determined by another, must have life in the most perfect degree. Such is God; and hence in Him principally is life. From this the Philosopher concludes (Metaph. xii, 51), after showing God to be intelligent, that God has life most perfect and eternal, since His intellect is most perfect and always in act. ST I, Q. 18, A. 3 --- Whether death and other bodily defects are the result of sin?  I answer that, One thing causes another in two ways: first, by reason of itself; secondly, accidentally. By reason of itself, one thing is the cause of another, if it produces its effect by reason of the power of its nature or form, the result being that the effect is directly intended by the cause. Consequently, as death and such like defects are beside the intention of the sinner, it is evident that sin is not, of itself, the cause of these defects. Accidentally, one thing is the cause of another if it causes it by removing an obstacle: thus it is stated in Phys. viii, text. 32, that "by displacing a pillar a man moves accidentally the stone resting thereon." In this way the sin of our first parent is the cause of death and all such like defects in human nature, in so far as by the sin of our first parent original justice was taken away, whereby not only were the lower powers of the soul held together under the control of reason, without any disorder whatever, but also the whole body was held together in subjection to the soul, without any defect, as stated in the I:97:1. Wherefore, original justice being forfeited through the sin of our first parent; just as human nature was stricken in the soul by the disorder among the powers, as stated above (Article 3; I-II:82:3), so also it became subject to corruption, by reason of disorder in the body. Now the withdrawal of original justice has the character of punishment, even as the withdrawal of grace has. Consequently, death and all consequent bodily defects are punishments of original sin. And although the defects are not intended by the sinner, nevertheless they are ordered according to the justice of God Who inflicts them as punishments. Reply to Objection 1. Causes that produce their effects of themselves, if equal, produce equal effects: for if such causes be increased or diminished, the effect is increased or diminished. But equal causes of an obstacle being removed, do not point to equal effects. For supposing a man employs equal force in displacing two columns, it does not follow that the movements of the stones resting on them will be equal; but that one will move with greater velocity, which has the greater weight according to the property of its nature, to which it is left when the obstacle to its falling is removed. Accordingly, when original justice is removed, the nature of the human body is left to itself, so that according to diverse natural temperaments, some men's bodies are subject to more defects, some to fewer, although original sin is equal in all. Reply to Objection 2. Both original and actual sin are removed by the same cause that removes these defects, according to the Apostle (Romans 8:11): "He . . . shall quicken . . . your mortal bodies, because of His Spirit that dwelleth in you": but each is done according to the order of Divine wisdom, at a fitting time. Because it is right that we should first of all be conformed to Christ's sufferings, before attaining to the immortality and impassibility of glory, which was begun in Him, and by Him acquired for us. Hence it behooves that our bodies should remain, for a time, subject to suffering, in order that we may merit the impassibility of glory, in conformity with Christ. Reply to Objection 3. Two things may be considered in actual sin, the substance of the act, and the aspect of fault. As regards the substance of the act, actual sin can cause a bodily defect: thus some sicken and die through eating too much. But as regards the fault, it deprives us of grace which is given to us that we may regulate the acts of the soul, but not that we may ward off defects of the body, as original justice did. Wherefore actual sin does not cause those defects, as original sin does. Article 6. Whether death and other defects are natural to man? Objection 1. It would seem that death and such like defects are natural to man. For "the corruptible and the incorruptible differ generically" (Metaph. x, text. 26). But man is of the same genus as other animals which are naturally corruptible. Therefore man is naturally corruptible. Objection 2. Further, whatever is composed of contraries is naturally corruptible, as having within itself the cause of corruption. But such is the human body. Therefore it is naturally corruptible. Objection 3. Further, a hot thing naturally consumes moisture. Now human life is preserved by hot and moist elements. Since therefore the vital functions are fulfilled by the action of natural heat, as stated in De Anima ii, text. 50, it seems that death and such like defects are natural to man. On the contrary, (1) God made in man whatever is natural to him. Now "God made not death" (Wisdom 1:13). Therefore death is not natural to man. (2) Further, that which is natural cannot be called either a punishment or an evil: since what is natural to a thing is suitable to it. But death and such like defects are the punishment of original sin, as stated above (Article 5). Therefore they are not natural to man. (3) Further, matter is proportionate to form, and everything to its end. Now man's end is everlasting happiness, as stated above (I-II:2:7; I-II:5:3-4): and the form of the human body is the rational soul, as was proved in the I:75:6. Therefore the human body is naturally incorruptible. I answer that, We may speak of any corruptible thing in two ways; first, in respect of its universal nature, secondly, as regards its particular nature. A thing's particular nature is its own power of action and self-preservation. And in respect of this nature, every corruption and defect is contrary to nature, as stated in De Coelo ii, text. 37, since this power tends to the being and preservation of the thing to which it belongs. On the other hand, the universal nature is an active force in some universal principle of nature, for instance in some heavenly body; or again belonging to some superior substance, in which sense God is said by some to be "the Nature Who makes nature." This force intends the good and the preservation of the universe, for which alternate generation and corruption in things are requisite: and in this respect corruption and defect in things are natural, not indeed as regards the inclination of the form which is the principle of being and perfection, but as regards the inclination of matter which is allotted proportionately to its particular form according to the discretion of the universal agent. And although every form intends perpetual being as far as it can, yet no form of a corruptible being can achieve its own perpetuity, except the rational soul; for the reason that the latter is not entirely subject to matter, as other forms are; indeed it has an immaterial operation of its own, as stated in the I:75:2. Consequently as regards his form, incorruption is more natural to man than to other corruptible things. But since that very form has a matter composed of contraries, from the inclination of that matter there results corruptibility in the whole. In this respect man is naturally corruptible as regards the nature of his matter left to itself, but not as regards the nature of his form. The first three objections argue on the side of the matter; while the other three argue on the side of the form. Wherefore in order to solve them, we must observe that the form of man which is the rational soul, in respect of its incorruptibility is adapted to its end, which is everlasting happiness: whereas the human body, which is corruptible, considered in respect of its nature, is, in a way, adapted to its form, and, in another way, it is not. For we may note a twofold condition in any matter, one which the agent chooses, and another which is not chosen by the agent, and is a natural condition of matter. Thus, a smith in order to make a knife, chooses a matter both hard and flexible, which can be sharpened so as to be useful for cutting, and in respect of this condition iron is a matter adapted for a knife: but that iron be breakable and inclined to rust, results from the natural disposition of iron, nor does the workman choose this in the iron, indeed he would do without it if he could: wherefore this disposition of matter is not adapted to the workman's intention, nor to the purpose of his art. In like manner the human body is the matter chosen by nature in respect of its being of a mixed temperament, in order that it may be most suitable as an organ of touch and of the other sensitive and motive powers. Whereas the fact that it is corruptible is due to a condition of matter, and is not chosen by nature: indeed nature would choose an incorruptible matter if it could. But God, to Whom every nature is subject, in forming man supplied the defect of nature, and by the gift of original justice, gave the body a certain incorruptibility, as was stated in the I:97:1. It is in this sense that it is said that "God made not death," and that death is the punishment of sin. - ST I-II, Q. 85, A. 6